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ABSTRACT
Unresectable hepatic metastases of colon cancer poorly respond to
existing therapies and are a major cause of colon cancer lethality. Transcriptionregulating Mediator kinase CDK8, an early clinical stage drug target, is amplified or
overexpressed in many colon cancers and CDK8 expression correlates with shorter
patient survival. Here we show that CDK8 inhibition does not generally suppress
proliferation of CDK8-overexpressing colon cancer cells but nevertheless CDK8
knockdown by shRNA or CDK8 kinase inhibition by a selective small-molecule drug
candidate suppresses metastatic growth of mouse and human colon cancer cells in the
liver. This effect is due at least in part to the inhibition of already established hepatic
metastases, indicating therapeutic potential of CDK8 inhibitors in the metastatic setting.
In contrast, CDK8 knockdown or inhibition has no significant effect on the growth of
tumors implanted subcutaneously, intrasplenically or orthotopically in the cecum.
Mechanistically, the site-specific effect of CDK8 on colon cancer growth in the liver is
mediated through the downregulation of matrix metalloproteinase (MMP) inhibitor
TIMP3 via the TGFβ/SMAD-driven expression of a TIMP3-targeting microRNA, miR-181b,
along with the induction of MMP3 in murine or MMP9 in human colon cancer cells via
Wnt/β-catenin-driven transcription. These findings reveal a new mechanism for negative
regulation of gene expression by CDK8 and a site-specific role for CDK8 in colon cancer
v

hepatic metastasis. Our results indicate potential utility of CDK8 inhibitors for the
treatment of colon cancers that metastasized into the liver and suggest that CDK8
inhibitors may be considered in other therapeutic settings involving TGFβ/SMAD or
Wnt/β-catenin pathway activation.
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CHAPTER 1 GENERAL INTRODUCTION

Colorectal cancer and animal models
Colorectal cancer (CRC) refers to the cancer that develops from the large intestine
(colon) or the rectum, which, depending on the cause of its occurrence, can fall into two
groups, sporadic colon cancer and colitis-associated cancer1. Sporadic CRC usually starts
as a polyp, which is an abnormal growth on the inner surface of the colon or rectum and
with the mutation of Adenomatous polyposis coli (APC). However, in most cases polyps
are benign and the potential to become CRC depends on the polyp types, grade of
dysplasia, location and the tissue environment2. With the accumulation of mutations,
such as mutations of K-ras and p53, polyps will develop into carcinoma3. In the case of
sporadic CRC, the mutations are mainly due to chromosomal instability, microsatellite
instability and loss of function of the tumor suppressor genes such as APC. In the case of
colitis associated CRC, chronic inflammation induces oxidative stress, aberrant
inflammatory and tissue repair signaling, which further causes the activation of Wnt/βcatenin pathway and initiation of dysplasia4. Dysplasia will eventually progress to
carcinoma with sustained chronic inflammation1. In fact, inflammation, together with
other factors, can also promote CRC metastasis, where CRC cells invade though the
intestinal wall and spread into distant organs via blood and/or lymph system5.
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According to the Facts & Figures 2017-2019, CRC is the third most common
carcinoma worldwide, with estimated 95,000 newly diagnosed cases and 50,000 deaths
in the US in 2017. The current survival rate for CRC is 65% at 5 years and 58% at 10 years.
For the patients with localized stage CRC, the 5-year survival rate is 90%, however, for
the patients diagnosed with distant metastases, survival rates decline to 14%, which
accounts for about 24% of all CRC patients6,7. Liver is the most common organ of CRC
metastasis and CRC metastasis can also happen in the lungs, bones, peritoneum and
brain. For the patients with CRC metastasis, only 15-20% are suitable for surgery8.
However, the primary goal of surgery resection for CRC patient with metastasis is to
remove the local colon tumor and prevent other local complications. If there are only a
few metastases in the liver or lungs, surgical removal can improve survival. But in most
cases, metastatic tumors are usually scattered in organs at different sites and most of
them are beyond the detection capacity, and therefore are hard to be removed by
surgery. Even worse, surgery has been shown to induce metastatic colorectal cancer
tumor growth9. Nowadays, the first-line chemotherapies for CRC at different stages,
including metastatic disease, are 5-fluorouracil supplemented with folinic acid and
oxaliplatin or irinotecan (FOLFOX or FOLFIRI, respectively)10,11. Although they provide a
marginal survival advantage in metastatic colorectal cancer12, these chemotherapies
usually bring serious side effects due to the indiscriminate killing of proliferating cells
which limits the utility of these regimens. Several targeted therapies have been approved
in recent years by FDA, such as regorafenib, targeting new blood vessel growth, and
nivolumab in combination with ipilimumab, targeting the immune system13,14. New
2

therapeutic approaches and novel drugs for CRC, especially for CRC metastasis, are still in
great demand.
Animal models, especially mouse models, are of critical importance for anticancer
drug development, shortening research period and providing information that can’t be
obtained from humans directly. Due to the high reproductive efficiency and the
availability of inbred strains to diminish genetic and physiological variations between
individuals, mouse models are especially useful for drug efficacy testing15. However, only
about 5% of the anticancer therapies, although effective on animal models and entering
clinical trials, are approved by FDA for clinical use16, suggesting the mouse models may
not reflect the human disease faithfully. Full understanding of the scope of application of
different models is critical for proper experimental design. In this section, the current
laboratory mouse models for CRC research will be discussed.

Chemically induced CRC models
Unlike the high incidence of spontaneous CRC in human beings, mice rarely
develop CRC spontaneously, less than 1%17. High incidence of CRC in mice, necessary for
routine experimental use, can be induced by exposure to carcinogens 16. Currently, the
precursors of methylazoxymethanol (MAM), 1,2-Dimethylhydrazin (DMH) and the
metabolite azoxymethane (AOM) are the two most commonly used carcinogens for CRC
induction in mouse model. MAM, found in cycad seeds, can yield methyl diazonium ion,
which can alkylate macromolecules in liver and colon and lead to tumor development18.
Beta-catenin mutations, stabilizing beta-catenin, are very common in AOM induced colon
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tumors in mouse19,20. AOM is more frequently used than DMH due to greater potency
and increased stability21. AOM is usually administered repeatedly for 6-8 weeks via i.p. or
s.c. injection to induce colonic malignancy in mice and the tumor burden is evaluated
starting 30 weeks after the first injection of AOM. The mouse model induced by AOM
administration is very useful for studies on carcinogenesis and chemoprevention, such as
the role of diet-induced obesity on colon tumor development22 and evaluation of drugs
for chemoprevention23. AOM can be also administered with dextran sodium sulfate
(DSS) solution orally, which provides the current colitis induced CRC mouse model. The
combination of AOM and DSS induced colitis related CRC provides a useful model for
chemoprevention of CRC by targeting bowel inflammation24.

Genetically modified mouse models
Despite the evolutionary distance, the contents of the mouse and human
genomes are largely conserved25, and the signaling pathways involved in cancer are
comparable in both species26. The backgrounds of inbred laboratory mouse strains have
been well investigated providing valuable models for biology research at molecular level.
Genetically modified mice cultured in a controlled environment provide very useful
cancer etiology models.
ApcMin/+ models
Adenomatous polyposis coli (APC) gene is one of the key tumor suppressors in
human colon and is conserved in mammals27. ApcMin/+ mice were first derived from
ethylnitrosourea mutagenesis screen for C57BL/6 mice with multiple intestinal neoplasia
4

(Min)28. ApcMin/+ mice carry a nonsense mutation at codon 850 of the Apc gene and were
recognized as a mouse model paralogizing human familial adenomatous polyposis (FAP)
syndrome29. Apc gene was also found to be somatically altered in more than 80%
sporadic CRCs30. The homozygous ApcMin/Min are embryonic lethal28. ApcMin/+ mice develop
multiple neoplasias throughout the intestinal tract within several weeks after birth, and
are considered to be a valuable model for tumorigenesis research31. However, in this
model most of the tumors develop in the small intestine instead of colon32 and most of
the mice die from anemia and cachexia at 120 days of age33. Due to the short lifespan,
none of the neoplasias progress to adenocarcinoma and metastasis in these mice34.
Apc1638N/+ mice, with Apc chain-terminating mutation introduced into the germ line,
could live longer and liver metastases were detected in those mice that lived for more
than one year35. But since only a few mice could reach that age, this model is not good
for investigation that needs large groups, such as drug testing.
In order to generate more CRC models, further genetic mutations, especially
those in genes involved in different stages of CRC development, have been introduced
into Apc mutant mice. Through a great deal of cross breeding between different
genetically modified mice, K-ras mutation was found to be necessary for adenoma
formation and p53 inactivation was required for carcinoma formation36. Crossing of mice
carrying mutations of Braf (V637E) or Kras (G12V) with mice with inactivation of a tumor
suppressor gene, such as ink4a/Arf, p53 or Tgfbr II, with the ApcMin/+ background leads to
metastasis in different organs depending on the specific gene modification37,38. However,
none of these models are potent enough to produce metastasis with a high percentage
5

and short latency39. Research with these models generated a lot of key information about
the driver genes for different stages of CRC development39. However, the tumors derived
from genetically engineered mouse models (GEMMs) lack heterogeneity of genetic
background, which is initiated and maintained by the same genetic mutation, which is in
a striking contrast to the tumors from human being40. The lack of heterogeneity of
GEMM tumors limits their use to faithfully recapitulate human CRC for pre-clinical
studies. This is especially common in drug efficacy research. Some drugs are effective in
GEMMs with a simple and clear genetic background, however they fail in the clinical trials
due to the heterogeneity of human tumors41.

Tumor implantation models
The implantation of tumors in mice has been widely used since the
immunocompromised mice were discovered in 1960s. Implantation, especially
subcutaneous implantation, is an easy operation and of relatively low cost and thus
nowadays is widely used in the testing of novel therapeutics. Immortalized human CRC
cell lines with different genetic background are commercially available for subcutaneous,
orthotopic or intra-splenic implantation into immunocompromised mice, such as nude or
severe combined immune deficiency (SCID) mice. However, the tumors of these models
are derived from cell lines and lack heterogeneity as do the GEMM models. Patient
derived xenografts (PDX), samples derived directly from patient without selection, are
used to recapitulate heterogeneity in tumor, including not only the complexity of gene
mutations but also the microenvironment around tumor cells. The genetic and
microenvironment heterogeneity in PDX models can be kept for several passages but will
6

be lost eventually. PDX also requires access to human CRC tissue, which is not easily
available for most research labs. There are also immortalized mouse CRC cell lines
available, most of them generated by chemical induction, for syngeneic implantation in
immunocompetent mice for preclinical research, which is especially important for those
drugs that are involved in immune system modulation.
Subcutaneous implantation
Nowadays the most widely used CRC models are based on the subcutaneous
implantation with inoculation of a suspension of tumor cells in PBS or growth medium
without serum into the flank(s) of immunocompromised mice. Almost all the
commercially available human CRC cell lines are suitable for this model. The tumors in
the subcutaneous model are usually palpable in one week for CRC model and the tumor
volumes are conveniently obtained by measuring with caliper. At the end of experiment,
the subcutaneous tumors can be easily and rapidly removed and snap frozen for
subsequent RNA and protein analysis. However, the disadvantage of this type of model is
also obvious. The major and marked disadvantage is the microenvironment in
subcutaneous implantation, which is clearly different from that in human CRC tumor. The
interaction between tumor cells and stromal cells determines the gene expression
profile, metastatic behavior and overall and disease free survival of patients42. In the
subcutaneous implantation tumor model with tumor cell lines, stroma is seldom found. In
fact, the ratio of tumor cells and stroma stands as a robust independent prognostic factor
in colon cancer42. There are also no liver metastases reported in CRC subcutaneous
transplantation model.
7

Orthotopic implantation
Orthotopic implantation of CRC cancer in mouse models refers to the injection of
a suspension of tumor cells or a piece of tumor fragment from a mouse model or from a
patient directly into the caecum, colon or rectum of mouse. Since tumor growth in
caecum is less life-threatening than tumor growth in colon or rectum and caecum is
conveniently exteriorized, caecum is the most common site for CRC orthotopic
implantation. The wall of caecum or colon of mice is too thin for naked eye operation and
the implantation of tumor cells should be conducted under a stereo zoom microscope. A
suspension of tumor cells can be injected into the caecum wall and sealed with glue in
case of leakage. The fragment of tumor from other mice or a human patient can be
implanted under serosa membrane of caecum. Besides exposure of the abdominal cavity,
injection of tumor cells into rectum through anus has been tried, but tumor take rate was
relatively low and tumor burden in rectum posed problems with defecation which limited
the tumor size43. Compared to the subcutaneous model, orthotopic implantation mimics
the microenvironment of CRC tumor much better, since the tumor directly grows in the
colon-like environment. Tumor invasion and metastasis to distal organs, such as liver,
have been observed very commonly in this kind of models44. The metastasis rates in the
liver depend on the cell line and mouse strain. Intra-mural orthotopic implantation of
MCA-38 cells into C57BL/6 mice resulted in about 70% spontaneous liver metastasis after
8 weeks inoculation45. For CT26 mouse colon cancer cells, subserosal orthotopic
implantation in Balb/cByJ mice gave 100% primary colonic tumors, but only 8%
spontaneous liver metastases after 8 weeks of tumor growth. However, CT26-FL3 cells,
8

generated through 3 rounds of liver metastasis selection, gave 90% spontaneous liver
metastases in the same model46. For human CRC cell lines, such as HCT116 (one of 12
tested CRC cell lines), primary tumor take rates in orthotopic implantation into BALB/c
nude mice for 6-8 weeks was 100% and about 70% of mice were found with lymph node
metastases, however, no spontaneous liver metastases were found in this model47. In
contract to the latter study, HCT116 cells orthotopic injection into Swiss Nu/Nu mice
resulted in about 70% spontaneous liver metastases after 8 weeks inoculation48,
suggesting the importance of host environment during the process of tumor metastasis.
Compared to the subcutaneous model, the most important advantage of
orthotopic implantation is that it’s capable of mimicking the microenvironment of CRC,
which plays key roles in the growth and proliferation of cancer cells at the primary site49.
However, the limitation of this model is obvious. It is time and energy consuming to do
cell injection in abdominal cavity and meanwhile the growth of tumors adds burden to
the intestinal system, which could lead to mortality of experimental mice. The leakage of
tumor cells during operation can result in scattered and random tumors in abdominal
cavity including liver (arising not through the blood system but though leakage from the
injection site).
The metastasis mouse models
Due to the early detection of benign colonic adenomas, the mortality of colorectal
cancer decreased during the last 50 years50. However, treatments of metastatic CRC
metastasis are still relatively ineffective. Since the majority of CRC related deaths are
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caused by metastasis, it is extremely important to elucidate the mechanisms behind
tumor invasion and metastasis. The metastasis of tumor cells from the primary site to
remote site usually includes several successive steps: a) local invasion and intravasation,
b) dissemination through the circulation system, c) extravasation at the metastatic site,
d) colonization at the metastatic site51. The ideal model of metastasis should recapitulate
all the steps and mimic the mechanisms behind these processes, such as gene alterations
required for invasion and metabolism adaption for cell survival in circulation system and
so on. A good model also should be predictable and reproducible and be available to
validate novel therapeutics. However, there is no model that can meet all the
requirements. Models should be selected according to the experimental purposes. For
the drug development targeting CRC metastasis therapy, i.e. the metastatic tumors that
have already been established in the patients, models that mimic step d), colonization at
the metastatic site, should be the most suitable.
The most widely used models for CRC liver metastasis research are injection of
tumor cells into the spleen or portal vein of mice. The injected cells reach hepatic
microcirculation through hepatic portal vein and will be arrested by cell size or specific
adhesion between cells from hepatic microenvironment and newly arrived tumor cells52.
Some of the arrested cells undergo extravasation and finally form colonies in the liver,
while most of the injected cells will die and disappear. High rates of metastases usually
can be achieved in this model. Syngeneic injection of 0.1 million CT26 cells into spleens of
BALB/c mice resulted in 100% liver metastases in two weeks. Similarly, syngeneic splenicinjection with MCA38 cells in C57BL/6 mice also developed hepatic metastases with
10

100% occurrence53. The high rates of metastases were also observed in the xenograft
splenic injection of human colon cell lines in the immunocompromised mice. Splenic
injection of HCT116 at different cell numbers demonstrated 100% liver metastasis
establishment at 25 days after injection54. Splenectomy can be applied to eliminate the
effect of tumors in spleen and let the metastatic tumors fully develop in the liver,
especially for the survival studies55.
The splenic injection model provides several advantages for metastasis research.
As discussed above, this model can give about 100% metastasis formation, making it very
suitable for novel drug testing. Also this model is applicable for CRC hepatic metastasis
disease specific survival study since liver is the only metastatic organ. However, the
disadvantages of this model are also evident. It only mimics the last two steps of
metastasis, extravasation and colonization in liver. The dissemination steps of the process
of metastasis are missed. Surgery in this model requires well-trained person and is time
consuming. Since the metastatic tumors grow in the liver inside the cavity, it is very hard
to trace the growth of metastatic tumors. The tumor cells can be labeled with
fluorescence or bioluminescence by stable transfection or virus mediated transduction
and the signal can then be acquired by an in vivo imaging system, however, unlike the
subcutaneous model, the signal of fluorescence or bioluminescence is easily influenced
by the location of signal emitting cells.
Besides intrasplenic injection model, direct injection of colon cancer cells via
hepatic portal vein or in liver parenchyma has also been used to mimic clinically relevant
colon cancer hepatic metastasis56,57. Compared to splenic injection model, however,
11

portal vein injection usually results in rapid cell death of the injected colon cancer cells
and forms relatively less metastasis58. In the splenic injection model, the injected tumor
cells are accompanied by splenocytes, in a similar manner as bone marrow cells, which
protect tumor cells from stress-induced cell death58. Direct injection of colon cancer cells
into liver parenchyma also puts no metastatic selection pressures, such as the shear force
from blood stream, on the injected cells, which makes this model less clinically relevant59.
Summary
All the mouse models for colorectal cancer have contributed to our
understanding of the progression of human CRC, from carcinogenesis to remote
metastasis. Different models are applied for different kinds of research. The best
approximation of human cancer is achieved with the PDX model, which contains all the
tumor flora and extracellular matrix directly from human patients. However, due to the
immunological differences between two species, there are still great limitations for the
mouse models with patient derived samples, which are believed to best recapitulate
human CRC growth. That problem has been greatly relieved by the mice with humanized
immune system that are now available for PDX models, which may provide superb tools
for immunotherapy investigations60. Tumor implantation models remain the mainstay of
CRC drug testing and splenic injection offers the most reliable approach to testing new
therapies in a metastatic setting.
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Background of CDK8
Cyclin dependent kinases (CDKs) are a family of serine/threonine kinases whose
kinase activity is dependent on the binding of cyclin family proteins. At least 20
mammalian CDKs have been predicted and identified61,62 and can be roughly divided into
two broad categories: cell cycle related, such as CDK2, CDK4, CDK6; and transcription
regulation related, such as CDK7, CDK8, CDK962,63, although these two groups may
overlap in specific contexts64. CDK8 was originally identified in human cells as a potential
kinase partner of cyclin C (CycC)65. By physically binding CDK8, cyclin C protein can be
protected from degradation66,67. CDK8 was subsequently found to function, as both a
positive and a negative regulator of transcription in different contexts through different
mechanisms68. CDK8, together with its closely related paralog CDK19, further distinguish
themselves by being the only kinases in the Mediator complex69. The Mediator complex,
also called Mediator co-activator complex, is a multi-protein complex which functions as
a “bridge” connecting RNA polymerase II and transcription factors and sometimes
enhancer-binding factors, and thus bends the chromatin forming transcription
preinitiation complex70-72. CDK8 or CDK19, cyclin C, MED12 or MED12L and MED13 or
MED13L form CDK8/19 subcomplex module (CKM)73. CKM could be either in free status74
or associated with core Mediator (the Mediator complex without CKM) mediated by
MED1375 (Fig. 1.1). The components of CKM function differently in transcription
regulation76 and biological development77. Unlike most of the kinases, the roles played by
CDK8/19 can be kinase independent78,79. As a pair of paralogs, CDK8 and CDK19 are
interchangeable under specific biological conditions80, however, in most instances,
13

dysregulation of CDK8 or CDK19 causes distinct biological consequences, especially in
disease development. In this review, we provide an overview of our understanding of the
regulation of CDK8/19 expression, the roles of CDK8/19 in RNA transcription and disease
development, especially in cancers.

FIGURE 1.1 The Mediator kinase module and Mediator complex in gene transcription.
The Mediator kinase module and Mediator complex in gene transcription: CDK8,
CycC, MED12 and MED13 compose Mediator kinase module. The core Mediator complex
consists of roughly 26 subunits and it can be divided physically into three parts, head,
middle and tail. The Mediator kinase module and core Mediator complex are joined into
the whole Mediator complex by Med13. The tail part and middle part of the Mediator
complex can bind to transcription factors which may be subject to CDK8 kinase
phosphorylation. The tail part of Mediator complex can bind to the factors that recognize
enhancer elements and stabilize promoter/enhancer loops. CDk8 kinase module can also
be free from Mediator complex285.
14

Regulation of CDK8 expression
CDK8 is constitutively expressed in most types of cells and tissues, to some degree
like house-keeping genes. Compared to its extensively studied functions, the regulation
of CDK8 expression is less investigated, however, we will still review the regulation of
expression of CDK8 at the stages of mRNA synthesis, stability, alternative splicing and
protein stability (Fig. 1.2).
mH2A1
MacroH2A (mH2A) is an isoform of H2A histone variants, with a 30 Kd nonhistone domain (macro domain) at the C-terminus; it is generally considered to be
transcriptionally repressive81. CDK8 expression is reversely regulated by mH2A1 at the
transcriptional level. A global decrease of the expression of histone variant macroH2A,
mH2A1 and mH2A2, was observed in highly malignant melanoma cells, those with
increasing metastasis potential, and in the metastatic sites compared to primary
melanoma82. Gene expression profiling demonstrated that the expression of CDK8
increased dramatically in the cells with mH2A1 or mH2A2 stable knockdown; in the highly
malignant melanoma cells mH2A was found enriched at the CDK8 promoter by chromatin
immunoprecipitation (ChIP) analysis; by quantitative PCR (qPCR) and
immunohistochemistry (IHC) analysis of fresh melanoma specimens, the expression of
CDK8 and mH2A were significantly inverse correlated82. Knockdown of CDK8 could largely
reverse melanoma cell proliferative advantage induced by mH2A loss82. The
downregulation of CDK8 expression by mH2A vanished in highly malignant tumors
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implying a role for CDK8 in melanoma metastasis. Similar phenomena were also observed
in breast cancer, with CDK8 expression upregulated while mH2A1 downregulated with
increasing breast cancer grade, and the expression of CDK8 and mH2A1 was significantly
inversely correlated83. All these data together suggest that CDK8 expression is repressed
by mH2A, directly or indirectly.
miRNAs
MicroRNAs (miRNAs) are a family of small noncoding RNAs containing about 22
nucleotides, which can bind to mRNA and negatively regulate their target genes84. The
expression of miRNAs is commonly dysregulated in cancer85. By dual-luciferase reporter
assay, CDK8 was identified as the target of miR-195-5p in colon cancer cells86. In breast
cancer cell line MDA-MB-231, miR-107 directly targeted 3’UTR of CDK8 and negatively
regulated CDK8 expression at mRNA and protein levels87. The same regulation was also
found in gastric cancer cells88 and non-small cell lung cancer cells89, in which CDK8 could
be inhibited by miR-107. Aside from miR-107, in breast cancer cells MDA-MB-231 and
MCF-7, miR-26b directly targeted the 3'UTR of CDK8 downregulating both CDK8 and βcatenin expression90. Recently, miR-26a, a tumor suppressor miRNA91, was
demonstrated to directly target CDK8 3’UTR and down-regulate its expression in
hepatocellular carcinoma cells, and consequently decrease the expression of c-Myc 92.
Interestingly, the relationship between miR-26a and CDK8/c-Myc shows negative
feedback regulation, which suggests that high level of CDK8/c-Myc inhibits miR-26a
expression while miR-26a targets and down-regulates CDK8/c-Myc92.
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Besides miRNAs, long non-coding RNA (lncRNA) also play an important role in the
regulation of CDK8 expression. H19, among other lncRNAs, was identified as the lncRNA
that was most significantly associated with survival by regulating RB1-E2F1 and β-catenin
activity, which have been shown to be regulated by CDK893,94. In fact, knockdown of H19
resulted in CDK8 downregulation in several colon cancer cell lines95.
Alternative splicing
RNA transcribed from DNA has to undergo splicing to remove introns and connect
exons and other processing to form mature mRNA. Alternative splicing results in different
mRNAs and different proteins, and thus regulates the abundancy, activity and stability of
target protein96. Through the analysis of RNA-Seq data of endothelial progenitor cells
followed by RT-PCR, cloning and Sanger sequencing, new transcript of CDK8 that lacks
exons 5 and 7 was discovered. Protein prediction of the new transcript revealed that the
new CDK8 isoform lacks proton and ATP binding residues as well as the entire cyclin C
binding domain and most of the protein kinase domain97. Alternative splicing has been
also observed for CDK19. Whole transcriptome sequencing of bone marrow biopsy
specimens from castration-resistant prostate cancer (CRPC) found high intronic read
death in CDK19 along with some other genes. Further analysis showed the majority of
CDK19 transcripts were inefficiently spliced in CRPC specimens98.
mTORC1
The expression of CDK8 was decreased and inversely correlated with the activity
of mTORC1 in the livers from human non-alcoholic fatty liver disease (NAFLD) and the
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leptin receptor-deficient (db/db) and leptin-deficient (ob/ob) mice, the most widely used
animal models for obesity with insulin resistance and fatty liver; inhibition of mTORC1
activity by Rapamycin or Torin 1 or shRNA significantly repressed the nutrient-repletion
induced CDK8 down-regulation both in vitro and in vivo; and also in contrast to increased
mTORC1 activation in liver during aging, the expression of CDK8 declined as mice get
old99. A recent paper showed that, in Drosophila cells, TORC1 induced CDK8 degradation
by ubiquitin/proteasome which could be reversed by MG132 treatment100.
In addition to degradation of CDK8, MED13/13L is also subject to
ubiquitin/proteasome system. Fbw7, the substrate recognition component of SCF (Skp–
Cullin–F-box) ubiquitin ligase, could bind to and promoted MED13/13L ubiquitylation and
degradation, and consequently dismantled CDK8/19 subcomplex module and presumably
changed its activity in transcription101.

FIGURE 1.2 The regulation of CDK8 levels in cells.
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The transcription of CDK8 can be repressed by mH2A; the mRNA level of CDK8
can be regulated by alternative splicing of pre-mRNA and targeted by miRNAs. CDK8
protein is also subject to proteasome degradation by mTORC1 mediated modification.

The difference between CDK8 and CDK19
CDK8 and CDK19 are evolutionary twins in the CDK family, and they diverged after
the emergence of vertebrates102. Compared with CDK8, CDK19 carries an extra
Glutamine-rich domain and Arginine/Serine-rich domain. Glutamine-rich domain in
eukaryotic transcriptional regulators acts as a functional modulator103,104 and is enriched
in metabolic processes103, while the Arginine/Serine-rich domain is mainly involved in
pre-mRNA splicing105,106. Despite 97% identity of amino acid sequence in the kinase
domain, CDK8 and CDK19 are different in many ways, especially in their biological
functions.
According to the Cell Atlas107, CDK8 together with MED12, MED12L, MED13,
MED13L localize exclusively in the nucleus, whereas CDK19 and cyclin C are found almost
equally in cytoplasm and nucleus, implying that CDK19 might function to a large degree
without Mediator complex (Fig.1.3 A). While CDK8 gene localizes to 13q12 region, CDK19
and CCNC genes localize to 6q21 region very closely to each other. The gene location and
cellular distribution suggests that CDK19 might interact even more closely with CycC than
CDK8 does. RNA-seq data of 17 cancer types by The Cancer Genome Atlas (TCGA)108
show that CDK8 is highly expressed in colorectal cancers while CDK19 was most abundant
in prostate cancers. Analysis of RNA expression in different human tissues by FANTOM5
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Cap Analysis of Gene Expression project109 reveals the different expression patterns of
CDK8 and CDK19, with high expression of CDK19 in brain and related tissues, such as
caudate, cerebellum, hippocampus and pituitary gland (Fig. 1.3 B).. Consistently with
these data, CDK19 was found disrupted in a female patient with congenital bilateral
falciform retinal folds, and Drosophila CDK8, the orthologue of both CDK8 and CDK19,
was a key regulator of dendritic development110. CDK8 and CDK19 are also not mutually
replaceable during mouse embryo development, CDK19 could not compensate CDK8
knockout induced embryo lethality111.

FIGURE 1.3 The distribution of CDK8 and CDK19 in tissues and in cells.
A. The information on Cyclin C, CDK19 and CDK8 distribution in cells is from CELL
ATLAS, which summarizes the distribution of proteins in several cell lines using several
antibodies. B. The expression of CDK19 and CDK8 in different human tissues obtained
through Cap Analysis of Gene Expression (CAGE) is reported as Tags Per Million,

20

generated by the FANTOM5 project. The orange line represents the average value of
gene expression from all tissues.
The gene expression changes in derivatives with the stable knockdown of CDK8 or
CDK19 were largely nonoverlapping in the routinely cultured HCT116 cells, or under the
specific conditions such as genotoxic stress stimuli and glucose deprivation112. However,
one should keep in mind that multiple phenotypic changes may arise from clonal
selection during the generation of stable knockdown cell lines. Also in HCT116 cells, CDK8
specific inhibition by gene modification decreased GLUT3 expression, however dual CDK8
and CDK19 inhibition induced GLUT3 expression significantly113. Considering that GLUT3
is the main glucose transporter in neurons114, induction of GLUT3 expression by
inhibition of CDK19 implies that CDK19 might play an important role in neuronal system
metabolism. Putting all the data together, CDK19 has a significant role in neuronal
system, which should be taken into consideration when developing drugs that target
CDK8 and CDK19.

The role of CDK8 in transcription
Dysregulation of transcription has been observed in a variety of diseases115.
Genome-wide location analysis by ChIP coupled with DNA microarray in yeast revealed
that core Mediator complex was co-localized with Pol II at the promoters of both inactive
and active genes, and CDK8 submodule largely overlapped with core Mediator by
transient interaction116. However, rather than as a general transcriptional factor,CDK8 or
CDK8 submodule functions as regulator of context specific gene expression, such as

21

during differentiation of budding yeast Saccharomyces cerevisiae 117, development of
drosophila larvae77 and mouse embryo111, with complicated and dramatic gene
expression changes in all these conditions. In routine cultured cells or the fully developed
organisms, where the gene expression is supposed to be stable, depletion of CDK8 does
not affect the cell or organism viability77,111,118.
CDK8 is capable of modulating transcription via the Mediator complex, which
plays fundamental roles in chromatin remodeling, preinitiation complex (PIC) and preelongation complex (PEC) formation71,119. CDK8, as well as CDK7 and CDK9, is able to
phosphorylate the carboxy-terminal domain (CTD) at Ser2 and Ser5120-122, modification of
which can facilitate or (as described in yeast studies) halt the transcriptional activity of
Pol II123. CDK8 can also directly phosphorylate transcription factors to potentiate their
transcriptional activity and/or alter their proneness to degradation (Fig. 1 4). We will
describe the role of CDK8 in transcription regulation in greater detail below.
Negative regulation
The initial research that investigated the role of CDK8 in transcription was in
yeast; Srb10, the yeast homolog of CDK8 was believed to generally repress transcription
in vivo124. Transcription and electron microscopy studies demonstrated that CDK8
subcomplex physically competed with Pol II binding to Mediator complex and thus
inhibited the necessary interaction between Mediator complex and Pol II within the
Preinitiation Complex78,125,126. However, the transcription inhibition by CDK8/19
subcomplex is kinase independent in human cells125. Mediator complex with or without
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CKM module purified from Hela nuclear extract showed different activities in Pol II
mediated transcription. The Mediator complex without CKM module exhibited higher
activity in enhancing transcription initiation and reinitiation, which was necessary for
continuous transcription127. In the HIV provirus infected Jurkat cells, the HIV promoter in
the viral long terminal repeat (LTR) was occupied by CDK8 module and transcriptionally
silent in the latent status; upon stimulation with TNF-α, CDK8 occupation disappeared in
the LTR promoter region and higher transcription of HIV related genes was observed
consequently128. Interestingly, in contrary to CDK8 protein itself, the kinase activity of
CDK8 was necessary for HIV-1-LTR-driven gene expression129, suggesting the kinase
dependent and kinase independent roles of CDK8 might totally deferent under certain
biological contexts. In addition to direct regulation of transcription, CDK8 can repress
cdk7 kinase activity by phosphorylation of cyclin H at Ser5 and Ser304, the kinase
subunits of the transcription factor II human (TFIIH) module130-132, which is necessary for
the release of Pol II from PIC to the pausing status133 (Fig.1.4 A).
Positive regulation
In addition to repressing transcription, CDK8 is capable of positively regulating
transcription. Yeast two-hybrid screening revealed that some transcriptional cofactors
bound to CDK8/CDK19 submodule directly134. In Hela cells, CDK8 interacted with viral
transactivators E1A and VP16 and functioned as a positive regulator in transcription135;
knockdown of CDK8 by siRNA repressed the transcription of exogenous Gal4-VP16 driven
luciferase136. CDK8 could also collaborate with TRRAP/GCN5L, an acetyltransferase, to
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result in tandem histone 3 phosphorylation/acetylation, which was correlated with
transcriptional activation, in the reconstituted human cell system and in HCT116 cells137.
CDK8 can also positively regulate transcriptional activity by directly modifying the
stability of Mediator complex components. CDK8 but not kinase dead mutant CDK8 has
been shown to interact with and phosphorylate Med3, a potent activator of transcription
in Mediator complex; phosphorylation of Med3 at S191 residue led to its interaction with
Grr1, a E3 ligase, and finally ubiquitination and degradation in yeast138 (Fig.1.4 B).

FIGURE 1.4 CDK8 regulates transcription.
A. CDK8 is capable of repressing Pol II mediated transcription by physically
preventing Pol II binding to Mediator complex and by disabling CDK7 by phosphorylation
of CycH, which primes CycH degradation. B. CDK8 can also promote Pol II mediated
transcription by stabilizing Mediator complex components (Med3), recruiting histone
acetyltransferase (GCN5) and transcription factors, which can be subject to CDK8
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mediated phosphorylation. CDK8 can also phosphorylate the C-terminal domain (CTD) of
Pol II directly.
CDK8 seems to exert a significant effect on the expression of super-enhancer
related genes. By using chromatin immunoprecipitation followed by sequencing (ChIPseq), CDK8/19, together with Mediator complex and other transcription factors, CDK8
was found to be highly concentrated at super-enhancers in acute myeloid leukaemia
(AML) cells139. Inhibition of CDK8/19 with cortistatin A (CA), significantly induced the
expression of super-enhancer associated genes; and this was confirmed by W105M point
mutation of CDK8/19, conferring resistance to CA, in which the gene induction effect of
the inhibition of CDK8 by CA was largely abolished139.
The role of CDK8 in regulating the activity of transcription factors
Transcription factors are highly evolutionarily developd and responsible for
allowing cells to make quick and appropriate responses to extracellular changes by
regulating gene expression. Transcription factors involved in different signaling pathways
play the key role in multicellular organism development140. Many studies have
demonstrated that CDK8 is a versatile regulator of several transcription factors.
C/EBPβ
The transcription factor CCAAT-enhancer-binding protein β (C/EBPβ) promotes
gene expression by binding to the target gene promoter and recruiting Mediator
complex. CDK8 plays two opposite roles under different situations.
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In vertebrate cells, upon the activation of C/EBPβ mediated transcription, the
CKM must be replaced by other proteins to remove its inhibitory effect141. Indeed,
Mediator complex CKM can recruit histone arginine methyltransferase PRMT5 to the
promoter of C/EBPβ target genes and cause symmetric demethylation of H4 arginine 3
(H4R3me2s) in the promoter regions of those genes, and consequently transcription
repression142. In Toll-like receptor 9 (TLR9) mediated innate immune related gene
expression, C/EBPβ together with CKM are also recruited to the promoter region,
however, without PRMT5 and no change in H4R3me2s level. Instead, Mediator complex
with CKM recruits general transcription factors TFIIE and TFIIB and functions as
transcription activator under these conditions143.
Β-catenin
The Wnt/β-catenin pathway plays a vital role in stem cell renewal and
organogenesis and is activated in many types of cancer144. Cdk8 is capable of
upregulating β-catenin target gene expression by two ways: directly potentiating βcatenin mediated transcription and repressing E2F1 which has been shown to restrain βcatenin activity93,94
In two RNA interference (RNAi)-based loss-of-function screens in human HCT116
colon cancer cells, CDK8 was found to activate the canonical WNT/β-catenin pathway93.
Upon activation, β-catenin transactivation domain directly bound to and recruited
Mediator complex to Wnt-responsive genes. The direct interaction between β-catenin
and Mediator complex was mediated by MED12, a key member and stabilizer of CDK8
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mediator submodule, and ectopic expression of the peptide that mimics the potential βcatenin binding domain of MED12 disrupted the interaction and inhibited β-catenin
transcription activity76,145. CDK8 expression in colon cancer cell lines93 and clinical
colorectal cancers was correlated with β-catenin activation 146.
Another explanation of how Cdk8 regulates β-catenin activity comes from studies
in Drosophila and human cancer cells, in which CDK8 was demonstrated to be bound to
the transcription factor E2F1 and suppressed the inhibitory effect of E2F1 on β-catenin
activity94. The binding between E2F1 and CDK8 leads to E2F1 phosphorylation at S375.
E2F1 with S375 phosphorylation or with S375D mutation loses its inhibitory effect on βcatenin mediated transcription147.
STAT1
Signal transducer and activator of transcription 1 (STAT1), a latent transcription
factor involved in a variety of biological events, becomes phosphorylated and activated
by receptor associated kinases upon stimulation by cytokines, such as IFN-γ148. In
addition to being phosphorylated at tyrosine by its receptor associated kinase,
phosphorylation at S727 is necessary for STAT1 to achieve its maximal potential in
transcription induction149. CDK8 has been demonstrated to be the enzyme mediating
STAT1 S727 phosphorylation in mouse bone marrow-derived macrophages and human
tumor cells; knockdown of CDK8 by siRNA decreased the transcription of 69% of IFN-γ
induced genes, involved in antiviral response in mouse MEF cells150. The STAT1 S727
phosphorylation blockage by CDK8 inhibition has been observed in a variety of human
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cancer cell lines in cell culture induced by IFN-γ and in xenograft tumors in mouse, and
has been used as a biomarker for CDK8 inhibitor development151.
P53
By meta-analysis of Affymetrix microarray gene expression data of breast cancer
patients, the expression of CDK8, CDK19 and CCNC at mRNA level was found to be
strongly increased in tumors with mutant p53152. In fact, CDK8, together with cyclin C and
MED12 was recruited to p21 promoter, a key target gene of p53, for strong
transcriptional activation in response to p53-activating stimuli153; knockdown of CDK8 by
siRNA dramatically decreased Nutlin3 induced p21 expression without changing p53
level154. In the DNA damage context, CDK8 recruitment to the initiation site was also
required for p53 mediated p21 induction153. However, the effect of CDK8 on p21
expression might be kinase independent. This was shown for CDK19 in an osteosarcoma
cell line (SJSA), naturally lacking CDK8, where knockdown of CDK19 suppressed p53
target gene expression induced by 5-fluorouracil treatment and this effect could be
reversed by overexpression of wild type CDK19 as well as CDK19 with D151A or D173A
kinase-dead mutation79.
On the other hand, p21 was capable to bind CDK8 and stimulate its activity in
promoting the secretion of damage- and senescence-related tumor-promoting factors155.
Knockout of p21 or inhibition of CDK8 kinase activity by Senexin A significantly reduced
the expression of paracrine tumor-promoting factors induced by doxorubicin treatment
in HCT116, and inhibition of CDK8 with Senexin A reduced and delayed the formation of
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tumors in human A549 lung carcinoma mouse xenograft model pre-treated with
doxorubicin155, suggesting a potential application of CDK8 inhibitors in chemotherapy
induced relapse and metastasis.
Notch
The Notch signaling pathway plays a vital role in cell-cell communications and is
highly conserved in metazoan evolution156. Notch protein is a transmembrane receptor
that undergoes proteolysis upon activation leading to the production of a truncated
peptide, the ICN, which acts as a transcriptional activator in the nucleus. Upon activation
of Notch1, ICN1 domain is released from Notch 1 by γ-secretase and localizes to the
nucleus for targeting transcription. CDK8 together with CycC promoted PEST motif
hyperphosphorylation of ICN1 which caused ubiquitination by Fbw7/Sel10 ubiquitin
ligase 157,158, and consequently ICN1 was degraded by proteasome system159.
Interestingly, human T-lineage acute lymphoblastic leukemia is frequently associated
with PEST domain truncations160; cyclin C gene was deleted in a subset of acute
lymphoblastic leukemias161. The same mechanism is also observed in SREBP-1c mediated
transcription. CDK8 bound to and phosphorylated SREBP-1c at T402 and promoted
SREBP-1c ubiquitination and turnover, and consequently diminished SREBP-1c mediated
gene transcription in HEK293 cells162.
HIF1A
hypoxia-inducible factor 1A (HIF1A) is one of the key transcription factors
accumulated for gene induction when cells are suffering from hypoxia stress, such as cells
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in the middle of a rapidly growing tumor but without proper blood vessel formation163.
CDK8, but not CDK19 was shown to be required for maximum hypoxia induced gene
expression in HCT116 cells163. By CDK8 chromatin immunoprecipitation sequencing (ChIPseq) experiments in HCT116 cells, CDK8 was found broadly bound to the majority of
promoters of hypoxia induced genes under hypoxic conditions163. Stable knockdown of
CDK8 did not affect HIF1A binding, histone modification and preinitiation complex (PIC)
formation in this process, but significantly impaired RNAPII elongation, due to the failure
of recruitment of positive transcription elongation factor b (P-TEFb) and the formation of
super elongation complex. In fact, the promoters of hypoxia-inducible genes were
occupied by paused RNAPII transcription machine, and CDK8-Mediator complex and
super elongation complex were recruited to chromatin for maximum transcription by
HIF1A upon activation163. A very similar mechanism has been also observed in the
regulation of the expression of serum induced immediate early genes. CDK8 was found
not to be necessary for Pol II recruitment but required for assembly of elongation
complexes at serum response genes164.
TFG-β/SMAD pathway
TFG-β/SMAD pathway is highly involved in multiple biological functions, such as
embryo development165, tissue homeostasis166 and carcinogenesis167. CDK8 and CDK9
mediated phosphorylation of linker region of SMADs was observed in embryonic day (E)
13.5 mouse embryos and in BMP/TGF-β treated mammalian cells. The linker region
phosphorylation mediated by CDK8/9 recruits YAP, which promotes SMAD1
transcriptional action, with strong effects on BMP/Smad1 target gene expression168.
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Interestingly, while potentiating transcriptional activity, phosphorylation of linker region
by CDK8/9 further triggered additional linker region phosphorylation by GSK3 of SMADs,
promoting their degradation by Smurf1 mediated ubiquitination168,169. The dual roles of
CDK8, as potentiator and primer for degradation, provide a good demonstration of the
strict and finely tuned transcription regulation, which has also been observed in yeast170.

Effects of CDK8 on metabolism
Metabolism is one of the most key features of life, through which the organism
protects life from the law of increasing entropy. CDK8 has been demonstrated to play
several roles in metabolism regulation (Fig. 1.5).
Glycolysis
Inhibition of CDK8 kinase activity by non-hydrolysable ATP analogs in analogsensitive CDK8 mutant cells, genetically modified by F97G mutation of CDK8,
downregulated the expression of many genes involved in the glycolytic pathway.
Consequently, genetic inhibition of CDK8 kinase activity reduced glucose uptake and
glycolytic capability in HCT116 cells and sensitized the cells to 2-Deoxy-D-glucose (2DG),
an inhibitor of glycolysis pathway. Importantly, Senexin A, the dual CDK8/19 inhibitor,
could partially recapitulate the glycolysis repression role of genetic CDK8 inhibition and
sensitization of cancer cells to 2DG113. Consistent with the mammalian model, in
drosophila starved larvae, CDK8 kinase mutation enhances the expression of genes
involved in glycolysis100.
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Mitochondrion
Mitochondria are undergoing fusion and fission dynamically responding to various
cellular conditions171. Mitochondrial fission divides mitochondrion into smaller units and
is involved in many biological processes, such as assisting mitochondrial
neurotransmission in neuron development and mitochondrial degradation in response to
stress172,173. Cyclin C is required and sufficient for stress-induced mitochondrial fission.
Knockout of cyclin C showed no effect on mitotic cell division, however, it significantly
reduced cisplatin induced mitochondrial hyperfission in MEF cells174. Directly introducing
synthetic glutathione s-transferase-cyclin C fusion protein into CCNC-/- MEF cells resulted
in significant fragmentation of the mitochondria174. Since CDK8 exclusively localizes to
the nucleus, it seems not to be involved in the process of mitochondria fission, which
happens in the cytoplasm174. On the other hand, CDK19, similarly to cyclin C, is equally
distributed in both nucleus and cytoplasm and might play a role in cyclin C mediated
mitochondria fission.
Lipid metabolism
The role of CDK8 in lipid metabolism was first observed in drosophila larvae, in
which lipid accumulated when CDK8 or CCNC was null-mutated. Another experiment in
drosophila starved larvae also demonstrated that CDK8 kinase-dead mutation increased
lipid droplets significantly100. A similar phenomenon was also observed in mammalian
hepatocytes95,162. Knockdown of CDK8 or cyclin C by shRNA significantly upregulated fatty
acid synthase (FAS) expression at both mRNA and protein levels in HepG2 cells and
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consequently resulted in triglycerides accumulation. Further studies demonstrated that
CDK8 could directly phosphorylate SREBP-1 at T402 residue causing degradation of
SREBP-1 by ubiquitination system; knockdown of CDK8 or cyclin C increased SREBP-1
protein stability and nuclear distribution in mammalian cells162. In agreement with the
data in vitro, knockdown of CDK8 in mouse liver via tail vein injection of adenoviruses
expressing shCDK8 lead to upregulation of FAS and accumulation of palmitate and
triglyceride162. Interestingly, insulin treatment in vitro or stimulated in vivo via re-feeding
significantly reduced CDK8 protein levels and upregulated transcription of FAS in vivo
99,162,175,

suggesting an important role of CDK8 in lipid metabolism.

Autophagy
Autophagy is a conserved degradative process that provides energy or resources
to maintain homeostasis under various types of stress, during which macromolecules or
organelles are engulfed by autophagosomes and hydrolyzed following fusion with
lysosomes. mTORC1 is in the key position to inhibit autophagy 176 and CDK8 is one of the
targets of TORC1 and prone to be ubiquitinated and degraded after
phosphorylation100,101,177.
A possible role for CDK8 in autophagy can be hypothesized from the evidence
that CDK8 expression was down-regulated during aging99, while autophagy also declined
with age178. In mouse liver, autophagy could be induced by starvation179, and CDK8
protein was increased during this process99.
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In drosophila, CDK8 and CDC Like Kinase 2 (CLK2) together phosphorylated
cleavage and polyadenylation specific factor 6 (CPSF6) to regulate mRNA processing
involved in autophagy. Overexpression of Atg1, the central autophagy regulator, caused
autophagy in the drosophila eye, with a rough eye phenotype180. RNAi screen discovered
that knockdown of CPSF6, a member of cleavage and polyadenylation (CPA) complex,
could rescue the rough eye phenotype. CPSF6 with CPA complex bind to the 3’ UTRs of
Atg1 and Atg8a transcript and increase mRNA stability by regulating alternative splicing.
Further study demonstrated that the activity of CDSF6 was increased by CDK8 and DOA
mediated phosphorylation. A similar mechanism was also observed in mammalian cells.
In MCF-7 cells incubated in a starvation medium, knockdown of CPSF6 by shRNA or
inhibition of CDK8 kinase activity with Senexin A dramatically reduced LC3 puncta and
formation of lipidated form of LC3 (LC3-II), the necessary step for autophagosome
formation100. However, CDK8 and CDK19 have not been duplicated in drosophila, an
event that happened in vertebrates, and Senexin A does not distinguish CDK8 and CDK19,
suggesting the possibility that it might be CDK19 or CDK19 and CDK8 together that are
involved in transcript splicing regulation in mammalian cells, especially when the premRNA splicing related arginine/Serine-rich domain in CDK19 is considered, as descripted
above105,106. All these data suggest that CDK8/19 could be a key regulator of autophagy
by regulating specific mRNA alternative splicing and stability. In agreement with this,
another work performed in drosophila demonstrated that Cdk8/cyclin C were required
for 3’-end formation of snRNA, which is important for the proper function of the major or
minor spliceosome181.
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The role of CDK8 in diseases
CDK8 has been shown to be involved in several diseases, including metabolic
diseases, neuron related diseases, inflammation diseases, cardiovascular diseases and
cancer (Fig.1.5).

FIGURE 1.5 The physiological processes and diseases involving CDK8.
Metabolic syndrome
Metabolic syndrome refers to the following conditions: insulin resistance, visceral
adiposity, high blood pressure, dyslipidemia and high body mass index182. The
insensitivity of the energy detecting system, pancreatic islet insensitive to glucose and
liver, muscle and adipose tissue insensitive to insulin, is the etiology behind metabolic
syndrome183, and CDK8 seems to be highly involved in this etiology.
The expression of CDK8 is upregulated in patients with type 2 diabetes. Screening
of gene expression in pancreatic islet specimens from type 2 diabetes by microarray
discovered that CDK8 was highly expressed in diabetic donors relative to normal
donors184; single nucleotide polymorphism (SNP) map also revealed CDK8 as a potential
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candidate gene linked to type 2 diabetes185. However, in contrast with the situation in
type 2 diabetes, the expression of CDK8 is downregulated in the liver with high fat
deposition. In the mouse model, CDK8 and Cyclin C protein levels were lower in the liver
of mice that were fed compared to those that were starved162. In the two mouse models
with fatty liver, leptin receptor-deficient (db/db) and leptin-deficient (ob/ob) mice, the
expression levels of CDK8 and Cyclin C were also lower compared to those in wild type
mice99. The same situation was also found in people with NAFLD, who had lower CDK8
and Cyclin C expression in the liver99.
The nutrition related CDK8 expression is regulated via mammalian target of
rapamycin complex 1 (mTORC1), one of the key nutrient sensor complexes186. In rat
hepatoma FAO cells, nutrient-depletion decreased CDK8 expression, however, treatment
with mTORC1 inhibitors, Rapamycin and Torin 1, both effectively prevented nutrientdepletion induced down-regulation of CDK899. Liver specific Raptor knockout mice
showed significantly higher CDK8 compared with wild-type mice that were re-fed after
fasting. Inhibition of mTORC1 also reversed aging induced CDK8 down-regulation in
mouse liver99. Taken together, mTORC1 can down-regulate CDK8-Cyclin C in certain
physiological conditions and this regulation plays an important role in the metabolic
balance.
Cardiovascular disease
According to Centers for Disease Control and Prevention, heart disease is the
primary cause of death in the United States. CDK8 plays a role in cardiovascular disease in
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two aspects: by acting directly on cardiomyocyte development and by acting indirectly on
lipid biosynthesis. Transgenic mice with specific overexpression of CDK8 in
cardiomyocytes had enlarged atria and dilated ventricles and died prematurely with the
symptoms of heart failure (HF). Cardiomyocytes from CDK8 transgenic mice were longer
but thinner than from the wild type mice, the typical morphology change in progressive
dilated cardiomyopathy and consequently HF187.
Dyslipidemia has been well demonstrated to be related to cardiovascular
disease188-190. The SREBP transcription factors play central roles in the regulation of lipid
biosynthesis and are conserved in evolution191,192. CDK8 phosphorylated SREBP1 protein
at T402, which resulted in proteasome-mediated degradation of SREBP1 and repressed
lipid-synthesis related gene expression. Specifically, knockdown of CDK8 in liver by tail
vein injection of adenovirus expressing shRNA against CDK8 caused accumulation of
triglycerides in liver and in plasma162. Interestingly, re-feeding significantly decreased
CDK8 and cyclin C in the nuclei and upregulated nuclear SREBP-1c level, suggesting the
involvement of CDK8 in nutrient related gene regulation162. In a naturally CDK8 depleted
cell line, knockdown of CDK19 significantly enhanced expression of genes related to lipid
and steroid biosynthetic process79.
In addition to CDK8, other members of CKM are also involved in cardiovascular
disease. Missense mutation of MED13L has been observed in patients with congenital
heart defect (transposition of the great arteries)193. In a mouse model, Med12
hypomorphism caused cardiac malformations and embryonic lethality at E10.5194.
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Diseases of Neural system
A case study showed that CDK19 was disrupted in a female patient with
congenital retinal fold and microcephaly and was believed to be the causative factor110.
Since CDK8 and CDK19 diverge only in vertebrates, the roles of both CDK8 and CDK19 in
vertebrates are believed to be substituted by CDK8 in lower level organisms. In
drosophila dendritic cells, related to mental retardation in the fly model, knockdown of
CDK8 dramatically reduced dendritic branching110. In another drosophila model, by
genetic mapping using single nucleotide polymorphisms, CDK8 was discovered to be
associated with visual system wiring195. CDK8 kinase mutation in drosophila resulted in
thicker and darker bristles, sensor for air flow on legs 77. In C. elegans, CDK8 and other
proneural proteins were necessary for neurogenesis from a presumptive mesodermderived cell lineage131, and also required for proper axon navigation during
development196 .
According to an immunohistochemical study, Cyclin C was weakly expressed in
both neurons and astrocytes from the brain, however, strong staining was detected in
astrocytes and pyramidal neurons in Alzheimer’s Disease (AD), implying its possible role
in AD pathogenesis197. Altered Pol II CTD phosphorylation status and subcellular location
has been discovered in biopsy specimens from Alzheimer’s disease (AD) brains198.
Mouse with Med12 hypomorphic mutation died at embryonic day 10 with severe
defects in axis elongation and neural tube closure194. In patients, MED13L variants were
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associated with intellectual disability199, and mutations that affected MED13 function
were observed in patients with developmental delay and/or intellectual disability200.
Inflammation
Inflammation is a type of biological responses of body tissues to various stimuli
and it contributes to many normal physiological and pathological processes, such as
wound healing and cancer201. Interleukin 10 (IL10), a broadly expressed antiinflammatory cytokine202, has been proven to be negatively regulated by CDK8/19.
Through high-throughput assay a compound designated BRD6989 was found to enhance
IL-10 production in bone-marrow-derived dendritic cells (BMDCs) stimulated with
zymosan A. Kinome profiling identified CDK8, but not other kinases, as the BRD6869
specific target. Other CDK8/19 inhibitors, such as cortistatin A and CCT251921,
recapitulated the enhancing effect on IL-10 induction in BMDCs at reasonable
concentrations203. As a strong immune homeostasis regulating cytokine, recombinant IL10 coupled with other treatments has shown promising results in clinical trials for
Crohn’s disease and rheumatoid arthritis204,205. While the anti-inflammatory cytokine IL10
was upregulated upon CDK8/19 inhibition, IL8, a proinflammatory cytokine, was
downregulated upon CDK8/19 kinase inhibition by a series of specific inhibitors in coculture models206.
Activation of Toll-like receptor 9 (TLR9) by oligonucleotides(ODN) containing
unmethylated CpG motifs(ODN2006), mimic bacterial DNA, strongly activate NF-κB
signaling pathway and expression of inflammatory cytokines in myeloma-derived
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RPMI8226 cells. CDK8/19 and NF-κB together with other essential transcription factors
colocalized on the promoters of inflammation-associated genes upon ODN stimulation
and knockdown of CDK8/19 by siRNA largely abolished TLR9 agonist induced
inflammatory cytokine expression143. CDK8/19 also plays an important role in TNFα /NFκB induced gene expression. Inhibition of CDK8/19 kinase activity by Senexin A or Senexin
B strongly depressed the early response gene expression induced by TNFα or IL-1, by
impairing elongation of transcription207. In addition, CDK8/19 was also found to be
necessary for human papillomavirus type 16 late gene expression by regulating
transcriptional elongation208.
All the above information suggests that CDK8 might be a good target for
inflammation control, by inducing anti-inflammatory cytokines and repressing TNFα /NFκB pathway activity.

Cancer
According to the Cancer Facts & Figures published by American Cancer Society,
cancer ranks second among the common causes of death in the US. CDK8/19 has been
demonstrated to be positively involved in the development of many types of cancer, such
as melanoma82, gastric adenocarcinoma209, colorectal cancer93,146, laryngeal squamous
cell carcinoma210, papillary thyroid211, pancreatic cancer212 and breast cancer213, and
others. Pathological specimen analysis demonstrates that CDK8 expression in colorectal
cancer and CDK19 expression in prostate cancer are highly elevated (Fig 1.6). We will
review the roles of CDK8/19 in different cancer phenotypes.
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Cancer promoting role of CDK8
Proliferation
The most important characteristic of cancer is uncontrolled growth of abnormal
cells. Dysregulation of Wnt/β-catenin pathway is implicated in the majority of colon
cancers. CDK8 was identified as a potentiator for Wnt/β-catenin pathway by two RNAibased loss-of-function screens93. Overexpression of CDK8 but not CDK8 harboring kinasedead mutation transformed NIH-3T3 cells and knockdown of CDK8 was reported to
dramatically inhibit the growth of HCT116 cells and other CDK8-overexpressing colon
cancer cell lines 93.

FIGURE 1.6 The expression of CDK8 and CDK19 in different types of cancer.
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RNA-seq data of 17 cancer types are reported as median FPKM (number
Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome
Atlas (TCGA).

Instead of CDK8, CDK19 was usually upregulated in prostate cancer cell lines
compared to benign prostate RWPE cells214. Simultaneous knockdown of CDK8 and
CDK19 significantly suppressed the proliferation in one of the tested prostate cancer cell
lines, VCaP 215.
Among all the studied malignancies, the activity of CDK8 was found to be the
most crucial for a subset of acute myeloid leukemias (AML). Inhibition of CDK8 kinase
activity with Cortistatin A dramatically decreased the growth of a subset of AML cell lines;
the specificity of the anti-proliferation effect of Cortistatin A was confirmed by CDK8/19
W105M mutation, which maintained kinase activity but produced resistance to inhibition
by Cortistatin A, and consequently the anti-proliferation effect of CA was obliterated in
W105M mutant AML cells139.
In contrast to proliferation promoting role in the above examples, knockdown of
CDK8, using CRISPR technology, did not significantly change cell growth in HPV16containing keratinocytes208. Knockdown of CDK19 or CDK8 via siRNA did not reduce
proliferation of prostate cancer cells, but reduced cell migration (VCaP was not tested in
that study)214. In addition to these findings, most of the developed CDK8/19 inhibitors
failed to recapitulate the growth repression effect in HCT116 colon cancer cells at
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concentrations that were effective in suppressing STAT1-s727 phosphorylation139,155,216,
and knockout of CDK8 and CDK19 did not show any effect on HCT116 cell viability 216.
The seemingly contradictory effects of CDK8 on cell proliferation might stem from
the variability of cell lines. The distribution of β-catenin seems to influence, at least in
certain models, the effect of CDK8 on cell proliferation. HCT116 cells are heterozygous
for a β-catenin mutation that confers resistance to degradation and are believed to be βcatenin dependent217. However, under normal growth conditions, the majority of βcatenin is distributed in the cytoplasm in HCT116 and HT29 cells while in SW480 and
DLD1 cells, most of the β-catenin stays in nucleus218-220. In agreement with this, our data
showed that inhibition of CDK8 with Senexin B had little effect on the growth of HCT116
and HT29 cells but significant growth inhibition over the long term was observed in
SW480 cells.
Dedifferentiation
Dedifferentiation, as a hallmark of many malignant tumors, refers to the tumor
cells bearing little or no resemblance to the cells that they originate from, a kind of
reverse differentiation221. Those tumors that highly express embryonic stem cell related
genes are usually poorly differentiated and have a poor clinical outcome222. CDK8 is
required for colon cancer cells to maintain dedifferentiation status. Inducible knockdown
of CDK8 in the mouse xenograft model of human colon cancer cell lines not only
significantly inhibited tumor growth but also induced tumor cell differentiation,
represented by more organized glandular structure and secreted mucin223. Interestingly,
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the expression of CDK8 decreased as normal mouse embryonic stem cell differentiated;
overexpression of CDK8 was capable of reversing mouse embryonic stem cell
differentiation by upregulating and activating MYC, implying a mechanism through which
high CDK8 expression induces tumorigenesis223. In agreement with these findings,
depletion of Mediator kinase module subunits, especially MED12 and MED13/13L,
resulted in downregulation of the expression of cancer-acquired super-enhancer
containing genes in colon cancer76. Correspondingly, in AML cell lines, only the cells with
a high level of stem cell related gene expression were sensitive to CDK8 inhibitor
treatment224.
EMT
Epithelial to mesenchymal transition (EMT), first described in embryonic
development, has been shown to play important roles in tumorigenesis, drug resistance
and metastasis225. In pancreatic cancer samples and cancer cells, CDK8 expression was
upregulated by K-ras activating mutation and was involved in EMT in pancreatic cancer.
Knockdown of CDK8 by shRNA neutralized the K-ras mutation induced EMT by regulating
EMT related gene expression in Wnt/β-catenin signaling pathway226. In addition, CDK8
protein levels were positively correlated with lymph node metastasis in laryngeal
squamous cell carcinoma (LSCC) patients; knockdown of CDK8 by siRNA expressing
lentivirus significantly repressed human LSCC cell migration and upregulated E-cadherin
expression, a hallmark of EMT changes227. Recently, selective inhibition of CDK8/19 by
Senexin B has been shown to abrogate BMP-induced EMT in a wide spectrum of cancer
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models, with downregulation of EMT-associated transcription factors and enhanced Ecadherin expression both in vitro and in vivo228.
Metastasis
About 90% of cancer death is caused by metastasis and conquering metastasis
would be the key to treating cancer229. Genome-wide chromosomal copy number
alteration analysis comparing paired primary and liver metastatic colorectal tumors
discovered amplification of CDK8 in some liver metastatic tumors while no amplification
was found in the paired primary tumors230; in clinical colorectal adenocarcinoma analysis,
CDK8 expression was significantly positively correlated with lymph node metastasis or
distant metastasis231. CDK8 expression was also upregulated in human LSCC compared to
normal controls and overexpression of CDK8 was positively correlated with lymph node
metastasis and significantly shorter overall survival227. Consistently, miR-101, targeting
CDK8, was downregulated in LSCC tissues and negatively correlated with tumor grade
and lymph node metastasis; overexpression of miR-101 suppressed LSCC Hep-2 cells
proliferation and migration210. CDK8 was also found to be positively correlated with
carcinogenesis and tumor progression, especially lymph node metastasis in gastric
adenocarcinoma209. Additionally, in diethylnitrosamine (DEN)-induced liver cancer model,
miR-26a, targeting CDK8, when administered by AAV-delivery system significantly
reduced lung metastasis92. While there was no effect on cell proliferation, knockdown of
CDK8 or CDK19 in prostate cancer cell lines significantly repressed the invasion and
migration in trans-well experiments214. In fact, CDK19 expression was higher in metastatic
prostate tumors than in paired primary tumors and was associated with unfavorable
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prognosis214. In another study, selective depletion of CDK8 in natural killer (NK) cells
significantly reduced B16F10 mouse melanoma cells lung metastasis, as measured by
pulmonary tumor nodules per lung.
Immune surveillance
As discussed above, CDK8 is one of the key kinases that are responsible for basal
phosphorylation of STAT1-S727, including NK cells232. Mutation of the phosphorylation
site (STAT1-S727A) targeted by CDK8 robustly enhanced in vitro-expanded NK cell
cytotoxicity toward leukemic cells. In addition, mice harboring STAT1-S727A mutation
survived significantly longer than STAT1-/- and wild-type mice when intravenously
transplanted with v-abl-transformed leukemic cells232. Through enhanced tumor
surveillance, STAT1-S727A mice were highly resistant to 4T1 breast cancer metastasis232.
In accordance with these data, conditional ablation of CDK8 in NK cells enhanced NK-cell
cytotoxicity in vitro and improved tumor surveillance in vivo. Mice with CDK8-deficient
NK cells were more resistant to v-abl+ lymphoma, and Abelson Murine Leukemia virus
(A-MuLV)-induced slowly progressing pro-B cell leukemia, and B16F10 melanoma
metastasis233. It should be noted that ablation of CDK8 did not influence NK cell
development and proliferation233, suggesting limited side effects by targeting CDK8 in NK
cells.
Warburg effect
Warburg effect, in oncology, refers to the fact that most cancer cells produce
energy through inefficient anaerobic glycolysis instead of through mitochondrial
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oxidative phosphorylation. Warburg effect has been studied in the field of oncology for
almost a century, and its fundamental roles in tumor development have been established
by myriads of studies234. By comparing colon cancer cells with hypomorphic alleles
sensitive to a bulky adenine analog, created by a single point mutation in the kinase
pocket of CDK8, to wild type cells, treated with ATP analogs, CDK8 kinase activity was
found to increase the expression of many key components involved in glycolytic pathway.
CDK8 inhibition decreased glycolytic capacity as well as glucose transporter expression
and glucose uptake as a consequence. Importantly, CDK8/CDK19 specific inhibitor
Senexin A sensitized cells to pharmacological glycolysis inhibition, showing significant
synergy with 2-Deoxy-D-glucose treatment113, suggesting that CDK8 might be a potential
pharmacologic target for the treatment of tumors with impeded glycolysis.
Drug resistance
Drug resistance usually develops to both conventional and targeted cancer
therapies and is the reason why about 90% of chemotherapy fails235. Transcription
dysregulation is one of the main factors behind drug resistance in cancer236. CDK8 has
been demonstrated to be a promising target for estrogen receptor (ER)-positive breast
cancer, in both ER-targeting therapy drug resistance and ER-targeting drug potentiation
ways. Under estrogen depleted conditions, inhibition of CDK8/19 with Senexin B
dramatically suppressed the development of estrogen independence in ER-positive
breast cancer cells; inhibition of CDK8/19 by Senexin B also boosted the anti-tumor effect
of ER-inhibiting drugs on ER-positive breast cancer cell proliferation in vitro and xenograft
tumor growth in vivo213,237. Similarly, down regulation of CDK8 mediated by miR-107
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sensitized A549 non-small cell lung cancer cells to cisplatin89. Knockdown of CDK19
significantly improved nutlin-3 induced cell growth inhibition in SJAS cells, in which CDK8
expression was lacking; this effect was kinase activity independent, since it could be
reversed by overexpression of CDK19-D151A or CDK19-D173A and could not be
mimicked by Cortistatin A79.
Cachexia
Cachexia is one major cause of cancer-associated death, occurring in about 80%
of cancer patients238. Cancer cachexia is characterized by massive loss of body mass,
including the wasting of skeletal muscle, cardiac muscle and lipids238,239. TNFα was the
first cytokine identified in relation to cachexia and named as “cachectin” to emphasize its
important role in cachexia240,241. The role of TNFα in cachexia is primarily exerted through
the NF-κB pathway, activation of which reduces the cellular levels of MyoD protein and
inhibits myoblast terminal differentiation242,243. In fact, inhibition or ablation of NF-κB
signaling pathway by genetic methods or by chemical compounds significantly
ameliorated muscular dystrophy in several models244-246. CDK8/19 kinases, as mentioned
above, are required for full activation of NF-κB signalling pathway. Inhibition of CDK8/19
strongly suppresses the expression of early response genes induced by TNFα, with IL8 as
one of the most induced genes in almost all the tested cell lines207. Interestingly, specific
polymorphisms and upregulated expression of IL8 gene have been strongly associated
with cachexia in gastric, prostate and lung cancers247-250.
Sarcoma in fish
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In a very unique model, walleye dermal sarcoma virus infection causes seasonal
development and regression of dermal sarcoma in fish. The retroviral cyclin encoded by
walleye dermal sarcoma virus selectively enhanced CDK8 activity but did not change
CDK8 the spectrum of CDK8 target genes, which contributed to the oncogenic capacity of
walleye dermal sarcoma virus251.
Potential tumor-suppressive effects of CDK8
A potential tumor-suppressive role of CDK8 was suggested in endometrial cancer
cells based on the following observations: overexpression of CDK8 inhibited endometrial
cancer cell growth and migration while inhibition of CDK8 in endometrial cancer cells
promoted their growth and migration252. The tumor-suppressive effects of CDK8 in
endometrial cancer was suggested to be due to the fact that inhibition of CDK8
dramatically induced lipid synthesis which positively correlates with endometrial cancer
progression253. However, the methods of gene modification applied in that paper require
special attention, as the shRNA targeting GFP, used as the negative control in that study,
can be toxic to cells (as noted in our laboratory); and the activity of ectopically
overexpressed CDK8 was not verified.
In the Apc(Min) murine model, conditional depletion of CDK8 in intestinal
epithelium driven by villin promoter induced Cre expression enhanced tumor
aggressiveness, with no change in the number of developing tumor foci254. The authors
suggested, however, that this result need not be interpreted as a tumor-suppressive
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function of CDK8, but rather as evidence that tumors arising despite the lack of CDK8
could acquire a more aggressive phenotype in the course of carcinogenesis254.
In another study, ablation of Cyclin C impaired CDK8/19 kinase activity and caused
Notch1 intracellular domain (ICN1) hypophosphorylation; the phosphorylation of ICN1
was required for its degradation and activity under control255. knockout of cyclin C
resulted in upregulation of ICN1 and increased the number of thymocytes in the mouse
model; heterozygous cyclin C deletion enhanced T-ALL development in the Lck-LMO1
transgenic mice, identifying Cyclin C as a haploinsufficient tumor suppressor in T-cells158.
Somatic MED12 mutations that impaired Mediator complex kinase activity or
interaction between MED12 and other Mediator complex components were observed in
uterine leiomyomas256,257 and prostate cancer258. Frequent somatic mutations in exon 2
of MED12 occur in uterine fibroids, which disrupt allosteric activation of CDK8 and CDK19
in subcomplex module259. Significant mutations of MED12 that lead to CDK8/19
dissociation from core Mediator were observed in Chronic lymphocytic leukemia (CLL)
and such mutations were associated with poor prognosis260.

CDK8/19 as a target for drug development
Kinase inhibitors are one of the major areas in drug development261. For most of
the protein kinases, the “Asp-Phe-Gly (DFG)” motif, located at the beginning of the
activation loop, is highly conserved and plays the key role in the regulation of kinase
activity262. When the kinase is in active status, the DFG motif adopts the “in”
conformation, with the Asp residue flipped inward, which is favorable for the
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coordination of magnesium ion and ATP binding; when the kinase is in inactive status, the
DFG motif changes its conformation to the “out”, with the Asp residue oriented outward
and no longer favorable for the coordination of magnesium at the catalytic site262,263.
Corresponding to the DFG motif conformations, two main kinds of kinase inhibitors are
developed: type I inhibitors bind to the active conformation of the protein kinase and are
ATP-competitive264; type II inhibitors bind to the inactive confirmation of the protein
kinase and allosterically stabilize the catalytically inactive conformation263,264.
For most of the CDKs, the DFG region does not perform “in” and “out” structural
transition, exhibiting DFG “in” conformation in both active and inactive status265. As a
result, most of the inhibitors of CDKs are type I inhibitors. However, sorafenib has been
shown to bind to CDK8 catalytic cleft and then induced and stabilized a DMG “out”
confirmation of CDK8, equal to the DFG “out” confirmation in other kinases266. One thing
that should be noted is that type I CDK8 inhibitors usually give significant inhibition of
STAT1 S727 phosphorylation, but type II CDK8 inhibitors exhibit weak potency in the
inhibition of STAT1 S727 phosphorylation in cells267,268. Therefore, STAT1 S727
phosphorylation might not be a proper molecular marker for cell-based testing of type II
CDK8 inhibitors. Until now, most of the type II CDK8 inhibitors, such as sorafenib, linifabib
and the recently developed CCT251545268, are not specific enough, with broad off-target
kinase inhibition activities151,267.
Compared to the preimplantation embryonic death in CDK8 knockout mice, no
gross or histopathological abnormalities were observed in conditional CDK8 knockout in
young adult mice254 and NK cell-specific CDK8 knockout of mice233, suggesting that CDK8
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inhibition should have little toxicity. Many CDK8/19 inhibitors have now been developed
(Table 1). Several CDK8 inhibitors were discovered by cell based screening, such as
CCT251545 that was identified via WNT signaling dependent TCF-luciferase expression in
HEK293 cells268,269; Senexin A was identified by screening for inhibitors of p21-activated
transcription155. Nowadays, computer-aided drug design has been widely applied for
kinase inhibitor discovery. Three CDK8 inhibitors were computationally screened out
from a large library of drug-like molecules by using two complementary cascades virtual
screening methods270. Compound 16 was discovered trough Fragment-based drug
discovery (FBDD), through which the drug’s potency had been highly improved by
fragment modification based on the structure activity relationship (SAR)271. Compound
51 was derived from CCT251545 by scaffold-hopping and introduction of an amino
substituent to prevent oxidase-mediated metabolism, and demonstrated prolonged halflife in animal model272. By modifications at the morpholine moiety, Compound 4k turned
out to be resistant to deactivation and metabolism mediated by CYP3A4273, a member of
cytochrome P450 superfamily of enzymes274.
Considering the data from CDK8 conditional knockout model, more specific
CDK8/19 inhibitors, with fewer off-target effects on the host, will be continually
developed. In the future, CDK8/19 inhibition sensitive cancer cell lines should be selected
and applied for testing the therapeutic window of drugs in animal models. As discussed
above, other diseases besides cancer, such as Inflammatory bowel disease, diabetes and
cardiovascular disease, should also be considered as potential targets of CDK8/19
inhibitors, and side effects on the neural system should be carefully checked.
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Table 1.1 CDK8/19 inhibitors in development

inhibitor

IC50 in vitro

Compound

CDK8 = 2.5

4K

nM

T-474

Biological effect test

Reference

Resistant to

Inhibit pSTAT1-727 with EC50 8.4 nM.

273

CYP3A4 mediated

Suppress tumor growth (T/C 29%) in

degradation

RPMI8226 mouse xenograft model

CDK8 = 1.6

Potential and

Inhibit the growth of prostate tumor in

nM

applicable for

xenograft model

CDK19 = 1.9

215

animal study

nM
Compound

CDK8 = 3

Good oral

16

nM

bioavailability

W-34

CDK8 = 6.5

Type II kinase

nM

inhibitor

Enzyme activity-based test

271

275

Compound

CDK8 = 50

Shows antimicrobial activity.

5I

nM

Inhibits the growth of HCT116 cell

SEL120-34A

CDK8 = 4.4

Favorable

Inhibit the growth of a group of AMLs in

nM

pharmacodynami

xenograft model.

276

224

cs

52h

CDK8 = 0.76

Good oral

Inhibition of STAT1 phosphorylation and

nM

bioavailability

suppress tumor growth (T/C 1%) in

277

RPMI8226 mouse xenograft model

CDK19
=0.99 nM
MSC2530818

CDK8 = 2.6

excellent kinase

Suppresses STAT1 S727 phosphorylation and

nM

selectivity,

tumor growth in SW620 human colorectal

microsomal
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278

stability, and

carcinoma xenograft model after oral

orally bioavailable

administration

Compound

CDK8 = 1.5

Phenocopies

Inhibition of STAT1 phosphorylation and

32

nM

CDK8/19

weak antiproliferative activity in HCT116

knockout cells

cells

CDK8 = 2.3

Orally bioavailable

Reduction of tumor growth in SW620

nM

Minimize

xenograft model.

CCT251921

CDK19 = 2.6
nM

216

279

transportermediated biliary
elimination

Compound

CDK8 = 5.1

Orally bioavailable

Sustained inhibition of STAT1-727

51

nM

and decent half-

phosphorylation in SW620 xenograft model

life in vivo

following oral dosing.

Orally bioavailable

Sustains inhibition of STAT1-727

CDK19 = 5.6

272

nM
Compound

CDK8 = 10

18

nM

280

phosphorylation in SW620 xenograft model
following single oral dosing.

CCT251545

CDK8 = 9

>100-fold

inhibits STAT1-727 phosphorylation in colon

nM

selectivity over

cancer cell lines.

291 other kinases

Suppresses growth of WNT-dependent

268

tumors.

Cortistatin A

CDK8 = 12

Reduces proliferation of JAK2-mutant AML

nM

and most myeloproliferative neoplasms in
vivo.
Suppresses Tat-dependent HIV transcription
and in vivo HIV rebound.

54

139,281-283

Senexin A

CDK8 = 280
nM

Highly selective

Delays NICD degradation in NOTCH1 mutant
CLL.
Decreases migration and invasion of prostate
cancer cells. Suppresses tumor growth of ERpositive breast cancer xenografts. Inhibits
chemotherapy-induced tumor-promoting
paracrine activity in mouse model.
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155,213,214,284

CHAPTER 2 RATIONALE OF THE INVESTIGATION
As mentioned before, it has been demonstrated that CDK8 is amplified and/or
overexpressed in a large fraction of colorectal adenocarcinomas146,231 and knockdown of
CDK8 by shRNAs was reported to suppress the growth of colon cancer cell lines that
harbored CDK8 copy number gain. The suppressing effect could be reverted by
overexpression of wild type CDK8 but not of CDK8 with kinase domain mutation93,
suggesting a kinase-dependent cell growth effect of CDK8. However, while a few drugs
developed to target CDK8 kinase activity showed an effect on colon cancer cell growth,
the majority of such drugs, including Senexin A and Senexin B developed by our lab,
exhibited little or no effect on colon cancer cell growth in vitro. Considering the
concentrations of drugs applied for in vitro experiments, more than hundred times higher
than IC50, and the potential off-target effects, not only on kinases but also on other
processes involved in cell proliferation, the probability of CDK8 kinase inhibition
restraining colon cancer cell growth seemed unlikely. On the other hand, higher CDK8
expression in the clinical colon cancer samples, detected by immunohistochemistry, was
associated with a poor prognosis146, implying that reduction of CDK8 expression might be
a method to improve survival of colon cancer patients. Putting all the information
together, the seemingly contradictory information raises two fundamental questions, a)
Do the inhibition of CDK8 kinase activity and depletion of CDK8 itself have the same
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influence on the growth of colon cancer cells; b) Is the unfavorable role of CDK8 in colon
cancer patients related to the growth of tumors at the primary site or to other reasons,
such as metastasis?
To address question a), we applied two separate approaches to inhibit CDK8
kinase activity and decrease CDK8 protein itself. CDK8 kinase activity can be inhibited by a
potent and selective CDK8 inhibitor, Senexin B, a Phase I clinical drug candidate (Fig. 2.1).
CDK8 protein knockdown can be performed by introduction of shRNAs into the target
cells. The growth of tumor cells, treated with Senexin B and/or with CDK8 knockdown by
shRNAs, will be investigated in vitro and in vivo, subcutaneously, orthotopically for
primary tumor model and in the liver for metastatic model.
With the data generated by the above studies, the molecular mechanisms behind
the experimental phenomena that will show significant changes upon CDK8 inhibition
will be investigated by high-throughtput microarray analysis and confirmed by qPCR and
western blotting. To validate the candidate signal pathways that are involved in CDK8
related biological phenomena, expression modification of the pertinent genes,
knockdown by shRNA or overexpression by corresponding full-length cDNA vextors, will
be carried out to diminish or enhance the biological effects of CDK8 inhibition.
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FIGURE 2.1 Inhibitory effect of Senexin B on 451 kinases.
Kinome profile was determined by ATP analog binding competition assay. Inhibited
kinases are marked with red circles and circle size is proportional to percentage inhibition
at the tested concentration (2 µM).
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CHAPTER 3 EXPERIMENTAL RESULTS

Inhibition of CDK8 does not block colon cancer cell proliferation in culture.
CDK8 is frequently amplified in colon cancers 286, and elevated CDK8 protein was
associated with increased colon cancer specific mortality 287. Since CDK8 or its paralog
CDK19 function in complex with cyclin C (CCNC), MED12 and MED13 151, we used
SurvExpress RNASeq database to investigate whether CDK8, CDK19, CCNC, MED12,
MED13 and MED13L (a paralog of MED13) are differentially expressed between equalsize high-risk and low-risk populations of 797 colon cancer patients. Most of these genes,
except CCNC and MED12, were expressed at much higher levels in the high-risk group,
with CDK8 showing the greatest differential (Fig 3.1A). Kaplan-Meyer analysis showed
shorter disease-specific survival of patients with highest CDK8 RNA expression (Fig. 3.1B),
in agreement with previous protein studies 287.
We analyzed the effects of CDK8/19 inhibition on in vitro growth of three CDK8overexpressing human colon cancer cell lines: HT29 and SW480 where CDK8 gene is
amplified and HCT116 where CDK8 is overexpressed without amplification 286. CDK8
knockdown in these cells has been associated with decreased proliferation 286 but several
CDK8/19 kinase inhibitors failed to suppress their growth 288-290. We treated these cell
lines with a highly selective CDK8/19 kinase inhibitor Senexin B 291, which inhibits the
growth of leukemias 224 and breast cancers 213. 5-day treatment with 1 M Senexin B
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(corresponding to ~20 times IC50 in cell-based CDK8 activity assays) did not inhibit the
growth of any cell line (Fig. 3.2A). In contrast, STAT1 phosphorylation at S727, which is
exerted in part by CDK8 292, was decreased by Senexin B (Fig. 3.2B). We have also carried
out long-term (14-day) colony formation assays. 1 M Senexin B did not decrease
the colony number in HCT116 and HT29 compared to vehicle control (Fig. 3.2C,D) but
image analysis showed that average colony size was moderately reduced (1.39-fold in
HCT116, 1.85-fold in HT29). In contrast, SW480 (Fig. 3.2E) showed a decrease in both
colony number (4.47-fold) and size (2.78-fold) upon Senexin B treatment. Hence, CDK8
kinase inhibition in CDK8-overexpressing colon cancer cells does not affect cell
proliferation in the short term but moderately inhibits long-term cell growth in some cell
lines.

FIGURE 3.1 CDK8 expression correlates with colon cancer survival.
(A) Expression of Mediator-associated CDK module components in equal-sized
high-risk and low-risk groups of 797 colon cancer patients (RNA-Seq data from
SurvExpress). (B) Association of CDK8 expression with disease specific patient survival in
the same dataset.
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Stable CDK8 knockdown in HCT116 and HT29 reduced cell growth in prior studies
286.

However, establishment of stable CDK8 knockdown derivatives could involve

additional changes; indeed, HCT116 cells with CDK8 overexpressed CDK19 293. To avoid
changes associated with cell selection, we introduced CDK8-targeting shRNA into HCT116
cells using a doxycycline-inducible vector. Doxycycline treatment decreased CDK8
expression in these cells, with no effect on CDK19 (Fig. 3.2F), but did not inhibit cell
growth in a 5-day proliferation assay (Fig. 3.2G). In 14-day colony formation assays (Fig.
3.2H), doxycycline-induced CDK8 shRNA expression had minor effects on the colony
number (1.06-fold) and average colony size (1.22-fold).

CDK8 inhibition selectively suppresses colon cancer growth in the liver.
As the primary model for in vivo studies, we used murine CT26 colon cancer cells,
which form syngeneic tumors in Balb/c mice. CT26 carry a G12D KRAS mutation,
homozygous deletion of CDKN2A and are wild-type for APC and TP53 294 but Wnt/βcatenin responsive 295. Treatment with 1 M Senexin B did not inhibit CT26 growth in
short-term culture (Fig. 3.3A), despite inhibition of STAT1S727 phosphorylation (Fig. 3.3B)
(CT26 do not form colonies). We introduced two different CDK8 shRNAs (to control for
off-target effects) into CT26 cells, which robustly express CDK8 but not its isoform CDK19
(Fig. 3.3C); stable knockdown of CDK8 alone had no effect on the low CDK19 expression
(Fig. 3.3C). Both CDK8 shRNAs gave only modest (statistically insignificant) growth
inhibition in vitro relative to control cells expressing either insert-free vector or
scrambled shRNA (Fig. 3.3D).
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FIGURE 3.2 inhibition of CDK8 does not affect colon cancer cell proliferation.
(A) Effect of 1 M Senexin B on the growth of human colon cancer cell lines; cell
numbers measured in triplicates. (B) Effects of 3 hr treatment with 1 M Senexin B on
STAT1S727 phosphorylation and expression of STAT1 and CDK8 in human colon cancer cell
lines. (C-E) Effects of 1 M Senexin B on colony formation by HCT116 (C), HT29 (D) and
SW480 (E) cells (14 days, in triplicates), colony numbers are indicated. (F) Effects of
doxycycline-inducible shRNA expression (96 hr treatment with 1 μg/mL doxycycline) on
the expression of CDK8 and CDK19 RNA (qPCR) and proteins (inset) in HCT116 cells. (G)
62

Effects of 1 μg/mL doxycycline on the growth of HCT116 cells with doxycycline-inducible
CDK8 shRNA; cell numbers measured in triplicates. (H) Effects of 1 μg/mL doxycycline on
colony formation by HCT116 cells carrying doxycycline-inducible CDK8 shRNA (14 days, in
triplicates).
We tested the effects of CDK8 knockdown and Senexin B treatment on in vivo
growth of cells implanted subcutaneously (s.c.) in BALB/c mice and found only weak
effects on tumor growth (Fig. 3.3E-H). CDK8 knockdown also had no effect on tumor
growth in an orthotopic model (cecal injection) (Fig. 3.3I,J).

FIGURE 3.3 Effects of CDK8 inhibition on CT26 murine colon cancer growth.
(A) Effect of 1 M Senexin B on the growth of CT26 cells; cell numbers measured
in duplicates. (B) Effects of 3 hr treatment with 1 M Senexin B on STAT1S727
phosphorylation and expression of STAT1 and CDK8 in CT26 cells. (C) Effects of CDK8
knockdown by two shRNAs (shCDK8-1 and shCDK8-2) on the expression of CDK8 and
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CDK19. pLKO.1 insert-free vector was used as a control (CT26-pLKO.1). Knockdown was
confirmed by qPCR and immunoblotting (inset; CDK19 was undetectable by
immunoblotting). (D) Cell growth of control CT26 cell lines (CT26-pLKO.1 and CT26scramble) and CT26 cells with CDK8 knockdown (shCDK8-1 and shCDK8-2), cell numbers
measured in duplicates. (E,F) Effect of CDK8 knockdown on the growth of s.c. tumors
relative to CT26-pLKO.1 (control) (n=10). Tumor growth curve(E) and final tumor
weights(F) are shown (G,H) Effects of treatment with Senexin B on the growth of s.c. CT26
tumors. Mice received Senexin B (oral, b.i.d.) or vehicle control (n=10) when the tumor
volume reached ~200 mm3. Tumor growth curve(G) and final tumor weights(H). (I,J) Effect
of CDK8 knockdown on orthotopic tumor growth (cecal injection) relative to pLKO.1
(control) (n=10). Mice were euthanized 30 days after injection. Representative tumor
images (I); final tumor weights (J).
To evaluate the effects on metastatic tumor growth in the liver, we used a splenic
injection model, where tumor cells are injected in the spleen, from where they rapidly
migrate to the liver via the portal vein 296. 16 days after splenic injection, mice were
euthanized and weights of tumor-bearing spleens and livers determined. Representative
spleen and liver images are in Fig. 3.4A,E. Neither CDK8 knockdown (two shRNAs, Fig.
3.4B,C) nor Senexin B treatment (Fig. 3.4D) had a significant effect on splenic tumor
growth. In contrast, both CDK8 knockdown and Senexin B strongly decreased tumor
growth in the liver, as indicated by liver weight (Fig. 3.4F-H) and histological
measurements of tumor areas in liver sections (Fig. 3.4I-L).
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FIGURE 3.4 Effects of CDK8 inhibition on CT26 murine colon cancer hepatic metastasis.
Effects of CDK8 knockdown or inhibition on CT26 tumor growth in spleens and
livers after splenic injection. 2x105 cells were injected into spleens (n=10) and the mice
were euthanized 16 days after cell injection. (A, E) Representative images of tumorbearing spleens (A) or livers (E). (B,C,F,G) Effect of CDK8 knockdown (shCDK8-1 and
shCDK8-2) relative to control cells (pLKO.1 and scramble) on tumor growth in spleens
(B,C) or livers (F,G). Weights of tumor-bearing spleens and livers are shown. Dotted lines
indicate average weight of corresponding normal livers. P-values were determined by
two-tailed t-test. (D, H) Effects of Senexin B on tumor growth in spleens (D) or livers (H).
Senexin B (i.p., daily) or vehicle control (n=9) were administered from the day of injection.
(I,K) Representative H&E staining of hepatic metastases from experiments in P and N,
respectively. Scale bars: 2 mm. T: tumor. (J,L) Quantification of relative tumor area in the
liver from experiments in P and N, respectively (n = 5).
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To determine the effect of CDK8 inhibition on mouse survival of hepatic
metastasis, spleens were removed 1 min after tumor inoculation. Mice, euthanized upon
morbidity, showed extensive liver metastasis (Fig. 3.5A). Kaplan-Meier plots show that
both CDK8 knockdown in tumor cells and systemic Senexin B treatment significantly
affect survival, with the combination of CDK8 knockdown and Senexin B further
increasing this effect (Fig. 3.5B). Figs. 3.5C,D show independent experiments confirming
the effects of Senexin B treatment on the survival of mice injected intrasplenically with
parental (Fig. 3.5C) or CDK8 knockdown CT26 (Fig. 3.5D). The effect of Senexin B was
much stronger on parental than CDK8 knockdown cells.

FIGURE 3.5. Effects of CDK8 inhibition on the survival of mice with hepatic metastasis.
A: Representative macroscopic images of metastatic spread in mice from survival
studies. Left: metastasis-containing liver in the abdominal cavity. Right: the abdominal
cavity with liver removed. (B,C,D) Survival studies (Kaplan-Meier plots). Mice were
injected with 2x105 cells into spleen and spleens were removed 1 min after inoculation.
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Senexin B was administered from the day of inoculation. n = 10 in all experiments.
Differences in mouse survival were evaluated by the log-rank test. (B) pLK0.1 control and
shCDK8-1 cell lines, treated with vehicle or Senexin B (oral, b.i.d). (C) Parental CT26 cells
treated with vehicle or Senexin B (diet + oral). (D) CT26-shCDK8-1 cells treated with
vehicle or Senexin B as in (C).
To determine if the effects of CDK8 inhibition on liver metastases were due to
prevention of metastatic foci establishment or suppression of already established
metastases, we asked whether CDK8/19 inhibition can affect tumor growth in the liver
when the inhibitor is administered after establishment of metastases. Consistent with
previously described time to liver metastasis in this model 297, we found macroscopically
and microscopically detectable metastases in 3/3 livers of mice 7 days after splenic
inoculation (Fig. 3.6A), indicating that any effects after this point would involve
suppression of hepatic tumor growth. We compared the effects of Senexin B
administered (i) for two days prior to splenic inoculation, (ii) on days 1-7 (day 1 is the
inoculation day), (iii) on days 8-14, or (iv) on days 1-14. The weights of tumor-bearing
livers are in Fig. 3.6 B. Senexin B administration prior to inoculation had no effect on liver
metastasis. Drug administration on days 1-7 decreased liver weights although this effect
did not reach statistical significance. On the other hand, treatments administered on days
1-14 or 8-14 were efficacious in suppressing hepatic tumor growth, indicating that CDK8
inhibition suppresses already-established liver metastases (Fig. 3.6B). This conclusion was
confirmed by a survival study, where Senexin B administration initiated on day 8 after
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splenic inoculation significantly extended mouse survival (Fig. 3.6C).

FIGURE 3.6 Effects of CDK8 inhibition at different stages of liver metastatic growth.
(A) Metastatic tumors in the livers of mice euthanized 7 days after splenic
inoculation of CT26 cells, detectable macroscopically (upper left, tumor marked with
arrow) and microscopically. Representative examples are shown. Scale bars: 0.2 mm. (B)
Effects of Senexin B treatment at different stages of liver metastasis on tumor growth in
liver. Mice (n=10) were treated with Senexin B (oral, b.i.d.) over two days prior to splenic
inoculation, during the first week after inoculation, during the second week after
inoculation, or over two weeks after inoculation of CT26 cells. Mice were euthanized two
weeks after inoculation; liver weights are shown. (C) Mouse survival study conducted as
in (Fig. 3.5 C) except drug treatment was started on day 8 after inoculation.

Effects of CDK8 are mediated via TIMP3 and MMP3 expression.
To understand the molecular mechanism of the effects of CDK8, a transcriptional
regulator, on liver metastatic growth, we carried out transcriptomic analysis of the
effects of CDK8 knockdown or Senexin B treatment in CT26 cells. Microarray
hybridization revealed strong effects on several members of the matrix
metalloproteinase (MMP) and tissue inhibitor of metalloproteinases (TIMP) families,
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specifically TIMP3 that was upregulated and MMP3, MMP10 and MMP13 that were
downregulated by CDK8 knockdown or inhibition (Fig. 3.7A-C), as validated by qPCR (Fig.
3.7D). Senexin B mimicked the effects of CDK8 shRNA in control cells but not in cells with
CDK8 knockdown (Fig. 3.7D).

FIGURE 3.7 CDK8 regulates the expression of TIMP3 and MMPs.
(A-C) Microarray analyses identify TIMP3, MMP3, MMP10 and MMP13 as CDK8
targets in CT26 cells. (A) Illumina microarray comparing CT26-shCDK8-1 vs. CT26-pLKO.1.
(B) Affymetrix microarray comparing CT26-shCDK8-2 vs. CT26-pLKO.1. (C) Affymetrix
microarray comparing CT26 parental cells treated with DMSO or 1 µM Senexin B for 24 h.
(D) qPCR analysis of the effects of CDK8 knockdown (shCDK8-1 and shCDK8-2) on the
expression of TIMP3, MMP3, MMP10 and MMP13, in the absence or presence of Senexin
B (1 M, 24 h treatment, in triplicates).
The effects of Senexin B on gene expression were concentration and time
dependent (Fig. 3.8A,C). Immunoblotting (Fig. 3.8B) confirmed concentration-dependent
TIMP3 induction and MMP3 inhibition by Senexin B. CT26 tumors growing in the livers of
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mice continuously treated with Senexin B also showed increased TIMP3 and decreased
MMP3, MMP10 and MMP13 (Fig. 3.9A).

FIGURE 3.8 TIMP3 or MMP3 expression analysis upon inhibition of CDK8 in vitro.
(A) Concentration-dependent effect of Senexin B (24 h treatment) on TIMP3 or
MMP3 expression (qPCR, in duplicates). (B) Effects of different Senexin B concentrations
(24 hr treatment) on TIMP3 and MMP3 protein expression. (C) Effects of long-term
treatment with 0.5 µM Senexin B for the indicated number of days on the expression of
TIMP3, MMP3, MMP10 and MMP13 (qPCR, in duplicates).
To determine if hepatic tumor growth is associated with altered CDK8, TIMP3 and
MMP3 expression, we compared RNA expression of these genes between CT26 grown in
culture or as tumors in spleen or liver. CDK8 was moderately elevated in splenic tumors
relative to cells in culture but greatly elevated in hepatic tumors (Fig. 3.11A). TIMP3 was
moderately increased in splenic tumors relative to cultured cells but decreased in hepatic
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tumors. In contrast, MMP3 was increased to a similar degree in both splenic and hepatic
tumors relative to cells in culture (Fig. 3.11A). We also analyzed transcriptomic data from
tumors formed by the parental CT26 and their derivative CT26-FL3 selected in vivo for a
high rate of hepatic metastasis following cecal implantation 299. Remarkably, CDK8 was
significantly elevated and TIMP3 downregulated in highly metastatic relative to parental
cells, whereas MMP3 elevation was not statistically significant (Fig. 3.11B).

FIGURE 3.9 TIMP3 and MMPs expression analysis in vivo.
(A) Effects of in vivo treatment with Senexin B on the expression of TIMP3,
MMP3, MMP10, MMP13 and CDK8 in hepatic metastases. Mice (n=6) received vehicle or
Senexin B (33 mg/kg, p.o., b.i.d.) starting from the day of splenic inoculation of CT26 cells
for 14 days. (B) RNA expression of TIMP3, MMP3, MMP10, and MMP13 in subcutaneous
CT26 tumors (n=3) or in the intestine (n=3). (C) Comparison of relative expression levels
of MMP3, MMP10 and MMP13 in intestines and s.c. CT26 tumors.
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FIGURE 3.10 Immunofluorescence analysis of timp3 and mmp3 in vivo.
(A,B) Immunofluorescence analysis of the effects of in vivo treatment with Senexin B (diet
+ oral) on days 11-14 after splenic inoculation on the expression of TIMP3 (A) and MMP3
(B) proteins in hepatic metastases. Scale bars: 20 μm.
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FIGURE 3.11 Metastasis related expression change of CDK8, TIMP3, MMP3.
(A) Expression of CDK8, TIMP3 and MMP3 in CT26 cells growing in vitro or as
tumors in spleen or in liver. Tumors were isolated from vehicle-treated mice (n= 3) 16
days after splenic inoculation. (B) Expression of CDK8, TIMP3 and MMP3 in tumors
derived from parental CT26 cells and their highly metastatic CT26-FL3 derivatives (data
from GEO: GSE67675).

To test the effect of TIMP3 on CT26 growth in the liver, we overexpressed human
TIMP3 in CT26 cells (Fig. 3.12A,B). This overexpression had no effect on endogenous
murine TIMP3 (Fig. 3.12B), CDK8 or MMP3 (Fig. 3.12C). TIMP3 overexpression did not
affect cell growth in vitro (Fig. 3.13A) or in vivo, when injected s.c. (Fig. 3.13B,C) or in the
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cecum (Fig. 3.13D,E). However, TIMP3 expression significantly increased mouse survival
of liver metastasis in the splenic injection model (Fig. 3.13F). The effect of Senexin B
treatment on mouse survival of tumors with TIMP3 overexpression (Fig. 3.13G) was much
weaker than its effect on parental CT26 tumors (Fig. 3.5B,C) and similar to its effect on
tumors with CDK8 knockdown (Fig. 3.5B,D).

FIGURE 3.12 Overexpression of human TIMP3 in CT26 cells.
(A) Expression of TIMP3 protein in CT26-VTIMP3 determined by immunoblotting.
CT26-VGFP used as control. (B) Analysis of the overexpression of human TIMP3 in CT26VTIMP3 and control CT26-VGFP cells (qPCR, in duplicates). (C) Analysis of CDK8 and
mouse TIMP3 expression in VTIMP3 and VGFP cells (qPCR, in duplicates).
MMP3 knockdown (Fig. 3.14A,B) had no significant effect on CDK8 or TIMP3
expression (Fig. 3.14C,D), cell growth in vitro (Fig. 3.15A) or tumor growth s.c. (Fig.
3.15B,C) but strongly increased mouse survival in the splenic injection model (Fig. 3.15D)
and lessened the survival effect of Senexin B (Fig. 3.15E). These results identify TIMP3
upregulation and MMP3 downregulation as events mediating the suppression of hepatic
metastasis by CDK8 inhibition.
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FIGURE 3.13. Effects of overexpression of TIMP3 on CT26 cells in vitro and in vivo.
(A) Dynamics of cell growth of VTIMP3 and VGFP cells in vitro. (B) Dynamics of
VTIMP3 and VGFP tumor growth and (C) final tumor volumes of VTIMP3 and VGFP
derivatives injected s.c. (n=10). (D) Images of representative orthotopic tumors formed by
VTIMP3 and VGFP cells after cecal injection. (E) Weights of orthotopic VTIMP3 and VGFP
tumors (30 days after cecal injection) relative to VGFP (control) (n=10). (F) Kaplan-Meier
survival plots of mice following splenic injection of VTIMP3 and VGFP cells. (G). KaplanMeier survival plots of mice following splenic injection with VTIMP3 cells and treatment
with vehicle or Senexin B. Survival studies and Senexin B treatment were conducted as in
Fig. 3.5 C.
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FIGURE 3.14 Knockdown of MMP3 in CT26 cells.
(A) Immunoblotting analysis of MMP3 protein knockdown with different shRNAs.
(B) Analysis of MMP3 knockdown by five different shRNAs. (C) qPCR analysis of CDK8 and
TIMP3 expression in MMP3 knockdown cells (qPCR, in duplicates).

CDK8 regulates TIMP3 and MMP3 expression and hepatic metastasis through
effects on TGFβ/SMAD-regulated miR-181b expression and the Wnt/β-catenin
pathway.
TIMP3 can be regulated by TGFβ/SMAD both positively 300 and negatively, via
SMAD-dependent microRNA expression 301,302. Importantly, SMAD activity is potentiated
by CDK8 228,303. To examine the role of TGFβ/SMAD in TIMP3 regulation by CDK8, we
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knocked down SMAD4, the common mediator of R-SMAD transcription factors 304 (Fig.
3.16A,B). SMAD4 knockdown had no significant effect on cell growth in vitro (Fig. 3.16C).
While CDK8 inhibition had no effect on SMAD4 expression (Fig. 3.16A), SMAD4
knockdown, like CDK8 inhibition, induced TIMP3 both at RNA (Fig. 3.16A) and protein
levels (Fig. 3.16B). The relative effect of Senexin B on TIMP3 was greatly diminished by
SMAD4 knockdown and the relative effect of SMAD4 knockdown was similarly reduced
by Senexin B (Fig. 3.16A). On the other hand, SMAD4 knockdown, in contrast to CDK8
inhibition, appeared to induce rather than inhibit MMP3 expression and did not interfere
with MMP3 inhibition by Senexin B (Fig. 3.16A). These results indicate that the effect of
CDK8 on TGFβ/SMAD mediates to a large extent the effect of CDK8 on TIMP3 (but not
MMP3) transcription.

FIGURE 3.15 Effects of overexpression of TIMP3 on CT26 cells in vitro and in vivo.
(A) Effect of MMP3 knockdown on CT26 cell growth in vitro (n = 10) (B) Effect of
MMP3 knockdown on the dynamics of CT26 tumor growth s.c. (n = 10). (C) Final tumor
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volumes of control and MMP3 knockdown derivatives injected s.c. (n=10). (D) KaplanMeier survival plots of mice following splenic injection of control and MMP3 knockdown
cells. (E). Kaplan-Meier survival plots of mice following splenic injection with MMP3
knockdown cells and treatment with vehicle or Senexin B. Mouse survival studies and
Senexin B treatment were conducted as in in Fig. 3.5 B.

FIGURE 3.16 Knockdown of SMAD4 in CT26 cells.
(A) Effects of SMAD4 knockdown by two different shRNAs on the expression of
SMAD4, TIMP3 and MMP3 in the absence or presence of 1 μM Senexin B (24 hr
treatment), (qPCR, in duplicates). (B) Effects of SMAD4 knockdown on the expression of
SMAD4, TIMP3 by western blotting. (C) Effects of SMAD4 knockdown on the growth of
CT26 cells.
Since TIMP3 was reported to be inhibited by several microRNAs including
TGFβ/SMAD-regulated miR-181b, as well as miR-21a, miR-21b, miR-125b1, miR-125b2
and miR-712 305-307, we measured the effects of Senexin B and CDK8 or SMAD4
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knockdown on the expression of these microRNAs. While most microRNAs were
unaffected by CDK8 inhibition (Fig. 3.17), Senexin B and CDK8 or SMAD4 knockdown
decreased miR-181b levels. The relative effect of Senexin B was greatly decreased in
CDK8 or SMAD4 knockdown cells (Fig. 3.17). A mimic of miR-181b transfected into
parental CT26 cells prevented TIMP3 induction upon treatment with Senexin B or by
CDK8 or SMAD4 knockdown compared to control cells (Fig. 3.18A,B). Conversely,
transfection of miR-181b antagonist into parental CT26 strongly induced TIMP3
expression, with a much weaker effect in cells with CDK8 or SMAD4 knockdown (Fig.
3.18C). These results indicate that CDK8 inhibition induces TIMP3 via SMAD-regulated
expression of miR-181b. Notably, while CDK8 regulated miR-181b (Fig. 3.17), miR-181b or
its antagonist had no effect on CDK8 expression (Fig. 3.18B,C).

FIGURE 3.17 Effect of CDK8 or SMAD4 knockdown on the expression of miRNAs.
Expression of the indicated microRNAs in CT26- pLKO.1, CT26-shCDK8 or CT26shSMAD4 cells untreated or treated with 1 µM Senexin B (24 hr treatment) (qPCR, in
duplicates) .
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FIGURE 3.18 The effect of miRNA181b on the expression of TIMP3.
(A) Expression of TIMP3 in CT26 cells transfected with control miRNA mimic or
miR-181b mimic, in the absence or presence of 1 µM Senexin B (qPCR, in duplicates) for
18 h (Senexin B treatment started 8 h after transfection). (B) Expression of TIMP3 and
CDK8 in CT26-pLKO.1, CT26-shCDK8 and CT26-shSMAD4 cells transfected with control
miRNA mimic or miR-181b mimic (qPCR, in duplicates). (C) Expression of TIMP3 and CDK8
in CT26-pLKO.1, CT26-shCDK8 and CT26-shSMAD4 cells transfected with control miRNA
mimic or miR-181b inhibitor (qPCR, in duplicates).
Several MMPs, including MMP3, are known transcriptional targets of wnt/βcatenin 308, which is regulated by CDK8 286. To determine if the effect of CDK8 on MMP3
could be mediated through wnt/β-catenin, we generated -catenin (CTNNB1) knockdown
derivatives of CT26 (Fig. 3.19A). CTNNB1 knockdown had no significant effect on cell
growth in vitro (Fig. 3.19E). Senexin B did not affect CTNNB1 expression (Fig. 3.19B) but
CTNNB1 knockdown mimicked CDK8 inhibition by downregulating MMP3 at both RNA
(Fig. 3.19B) and protein levels (Fig. 3.19D). The relative effect of Senexin B on MMP3 was
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greatly diminished upon CTNNB1 knockdown and the relative effect of CTNNB1
knockdown was similarly reduced by Senexin B (Fig. 3.19D). In addition to the strong
effect on MMP3, CTNNB1 knockdown moderately induced TIMP3 and showed a modest
effect on TIMP3 induction by Senexin B (Fig. 3.19C). These results suggest that the
Wnt/β-catenin pathway mediates to a large extent the effect of CDK8 on MMP3 and to a
lesser extent on TIMP3.

FIGURE 3.19 Knockdown of β-catenin in CT26 cells.
(A-C) Effects of CTNNB1 knockdown (A) by two different shRNAs on the expression
of MMP3 (B) and TIMP3 (C) in CT26 cells, in the absence or presence of 1 μM Senexin B
(24 hr treatment) (qPCR, in duplicates). (D) The effect of knockdown of CTNNB1 on the
expression of MMP3 by western blot. (E) Effects of CTNNB1 knockdown on the growth of
CT26 cells.
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We have also tested if STAT1, another pleiotropic transcription factor known to
be co-regulated by CDK8 292, is involved in TIMP3 and MMP3 regulation. While Senexin B
inhibited STAT1 phosphorylation at S727 (Fig. 3.20A), STAT1 knockdown had no effect on
TIMP3 or MMP3 expression (Fig. 3.20B).

FIGURE 3.20 Effect of knockdown of STAT1 on TIMP3 and MMP3 in CT26 cells.
(A) STAT1 knockdown by two different shRNAs in CT26 cells (immunoblotting). (B)
Expression of MMP3 and TIMP3 in CT26 cells with STAT1 knockdown (qPCR, in
duplicates).
We compared the effects of the knockdowns of CDK8, SMAD4 and CTNNB1 on
tumor growth in vivo, using s.c. and splenic injection models. CTNNB1 knockdown
significantly inhibited tumor growth s.c. (Fig. 3.21A) and strongly inhibited tumor growth
in the spleen (Fig. 3.21B), whereas neither CDK8 nor SMAD4 knockdown had significant
effects at these sites (Fig. 3.21A,B). In contrast, hepatic tumor growth was significantly
suppressed by CDK8, CTNNB1 or SMAD4 knockdown (Fig. 3.21C). Hence, both
TGFβ/SMAD and Wnt/β-catenin pathways regulate the growth of hepatic metastases in
this model, but only TGFβ/SMAD inhibition, like CDK8 inhibition, selectively affects liver
metastasis.
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FIGURE 3.21 Effect of the knockdown of cdk8, ctnnb-1 and smad4 on CT26 cells in
vivo.
(A) Effects of CDK8, CTNNB1 and SMAD4 knockdown on the growth of CT26 s.c.
tumors. 106 cells were injected s.c. and tumor weights were measured after 16 days.
CT26-pLKO.1 cells were used as control (n=10). (B, C) Effects of CDK8, CTNNB1 and
SMAD4 knockdown on CT26 growth in spleen (B) and liver (C) after splenic injection of
2x105 cells. Mice (n=10) were euthanized 16 days after injection.

CDK8 inhibition induces TIMP3, inhibits MMP9 and suppresses hepatic metastasis in
human colon cancer cells.
The effects of Senexin B on TIMP3 and different MMPs were analyzed in a panel
of 10 human colon cancer cell lines. Senexin B induced TIMP3 expression, with
statistically significant induction in 7 of 10 lines (Fig. 3.22). Among the MMPs, MMP9 was
inhibited by Senexin B in most cell lines (Fig. 3.22), whereas MMP3, MMP10, MMP13,
MMP2 and MMP7 were not significantly affected by the inhibitor (Fig. 3.22). Inducible
expression of CDK8 shRNA in HCT116 cells also induced TIMP3 and inhibited MMP9,
suppressing the effects of Senexin B on these genes (Fig. 3.23A,B).
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FIGURE 3.22. Effects of Senexin B on TIMP3 and MMPs in colon cancer cell lines.
Effects of Senexin B on the expression of different MMPs and TIMP3 in a panel of
human colon cancer cell lines. qPCR analysis of the effects of 1 µM Senexin B (24 h
treatment) on the expression of the indicated MMPs in the indicated cell lines (qPCR, in
duplicates).

FIGURE 3.23. Effect of knockdown of CDK8 on the expression of TIMP3 and MMP9.
(A,B) qPCR analysis of the effects of doxycycline-inducible CDK8 shRNA on TIMP3
(A) and MMP3 (B) expression in HCT116 cells. Cells were treated with 1 M doxycycline or
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vehicle control for 72 hrs, Senexin B was added where indicated for the last 24 h of this
treatment (all qPCR in duplicates).
We analyzed the effect of Senexin B on liver metastatic growth of human HCT116
cells in nude mice (Fig. 3.24B-E). Following splenic injection and spleen resection, mice
were treated with Senexin B or vehicle control. 7 weeks after tumor inoculation, mice
were euthanized and livers, all of which contained tumor metastases (Fig. 3.24B), were
weighed. Analysis of liver weights (Fig. 3.24C) and tumor areas in the liver (Fig. 3.24D,E)
showed strong inhibition of hepatic tumor growth by Senexin B. Notably, even the long
(7-week) Senexin B treatment showed no apparent toxicity (mouse body weights over
the course of the study increased by 9.4±1.3% in the control group and by 7.1±1.4% in
the Senexin B-treated group). In contrast to its effect on tumor growth in the liver,
Senexin B did not inhibit the growth of HCT116 tumors s.c. (Fig. 3.24A).

FIGURE 3.24. The effect of CDK8 inhibition on the tumor growth of HCT116 cells in vivo.
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(A) Dynamics of HCT116 tumor growth s.c. in mice treated with Senexin B (33
mg/kg, p.o., b.i.d) or vehicle control (n = 5). (B-E) Effect of Senexin B on HCT116 hepatic
metastasis. 106 HCT116 cells were injected into spleens and spleens were removed 1 min
after injection. Vehicle or Senexin B (oral, b.i.d., 5 days a week) (n=9) were administered
from the day of injection for a period of 6 weeks. B: Representative images of HCT116
tumor-bearing livers in mice treated with vehicle or Senexin B. C: Weights of tumorbearing livers. D: Representative H&E staining of hepatic metastases. T: tumor. Scale
bars: 1 mm. E: quantitation of relative tumor areas in the liver (n = 4).

Discussion

Mediator kinase CDK8 was first identified as an oncogene in colon cancer, where
CDK8 was found to be amplified in a sizable subset of tumors and to act as a positive
mediator of the Wnt/β-catenin pathway that plays a key role in colon carcinogenesis 286.
High CDK8 expression has been established as a negative prognostic marker in colon
cancer 287. Our analysis of the RNA-Seq database confirms this association and shows that
not only CDK8 but also CDK19 and their interactive proteins MED13 and MED13L are
expressed at a higher level in high-risk colon cancers, although CDK8 shows the strongest
correlations. CDK8 shRNA was reported to inhibit the proliferation of CDK8overexpressing colon cancer cells in vitro 286 and in vivo 309,310 but a variety of CDK8/19
kinase inhibitors failed to suppress the growth of colon cancers in vitro or in primary
tumors 288-290. (A moderate but significant effect on the proliferation and primary
xenograft growth of a small subset of colon cancer cell lines was observed with CDK8/19
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inhibitors that also showed a pronounced toxicity 206. However, transcriptomic analysis of
in vivo effects of these inhibitors indicated pleiotropic effects that were very different
from pathway-specific effects of another CDK8/19 targeting agent 224 suggesting possible
off-target activities.) In the present study, we tested three human colon cancer cell lines
(HCT116, HT29 and SW480) with CDK8 amplification or overexpression for the effect of
Senexin B, an early-stage clinical drug candidate which is highly selective for CDK8 and its
paralog CDK19 291, on cell proliferation. CDK8 kinase inhibition or inducible shRNA
knockdown in 2 of 3 cell lines was not associated with any effects on cell proliferation in a
5-day assay or on the number of colonies formed by these cells. However, in the third cell
line (SW480), CDK8 kinase inhibition had a notable effect on colony formation but not on
short-term cell growth. These results suggest that oncogenic effects of CDK8 in colon
cancer are not generally mediated by the effects of CDK8 on cell proliferation.

The different effects of CDK8 on long-term colony formation in different cell lines
might due to the distribution of β-catenin. HCT116 cells are heterozygous for β-catenin
mutation that renders it resistant to degradation and these cells are believed to be βcatenin dependent 217. HT29 and SW480 are wild-type for β-catenin but harbor APC
mutation, which slows down β-catenin degradation311. However, under the normal
culture conditions, the bulk of β-catenin is located in the cytoplasm in HCT116 and HT29
cells while in SW480 cells, most of the β-catenin stays in the nucleus 218-220. In
concordance with this, our data showed that inhibition of CDK8 with Senexin B had
limited effect on the colony formation of HCT116 and HT29 cells but significant inhibitory
effect was observed on SW480 cells.
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To determine if CDK8 inhibition could have an in vivo therapeutic effect on colon
cancer cells that do not respond to such inhibition in vitro, we have investigated the
effects of CDK8 knockdown or kinase inhibition on the growth of CT26 tumors implanted
at different sites and on liver metastases arising after splenic injection. We found that
CDK8 inhibition had no significant effect on the growth of colon cancer cells implanted
s.c., into the spleen or orthotopically into the cecum. However, both CDK8 knockdown in
tumor cells and treatment of mice with the CDK8 kinase inhibitor strongly suppressed
metastatic tumor growth in the liver. In accordance with the selective effect of CDK8
inhibition on tumor growth in the liver, CDK8 expression was selectively elevated in CT26
tumors growing in the liver and in a subline of CT26 cells selected for increased
propensity for liver metastasis46. While most of our in vivo studies were conducted in a
syngeneic mouse model, we have confirmed that the growth of hepatic metastases was
suppressed by the CDK8 inhibitor in CDK8-overexpressing human HCT116 cells, where
the inhibitor did not suppress cell growth in culture or in s.c. xenografts. Remarkably, a
recent study comparing the copy number profiles of paired primary and liver metastatic
samples from colon cancer patients identified CDK8 as one of the few genes that showed
selective gene amplification in liver metastasis relative to primary tumor 230, in
concordance with our results. The effects of the CDK8/19 inhibitor on metastatic growth
in the liver were associated with no apparent toxicity and no loss in mouse body weights
relative to the control. Importantly, suppression of liver metastasis by CDK8 inhibition
was exerted at least in part through the inhibition of tumor growth in the liver rather
than initial liver colonization, as indicated by the effects of treatment that was started
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after the establishment of liver metastases (one week after inoculation). Many anticancer
drug candidates show great efficacy in primary tumor models but are inefficient in
preclinical models of metastatic disease, providing a plausible explanation for the failure
of such agents in clinical trials of metastatic cancer 312. Our results reveal CDK8/19
inhibitors as a remarkable exception to this rule, which are active against the metastatic
disease even when inefficient against the primary tumors.

Since CDK8 is a nuclear protein that has no known functions other than
transcriptional regulation, we have used transcriptomic analysis to elucidate the
mechanism of the anti-metastatic effects of CDK8 inhibition. Strikingly, one of the genes
that was most strongly induced by CDK8 knockdown or Senexin B was TIMP3 and three of
the most strongly inhibited genes were MMPs. The effects of CDK8 inhibition on the
expression of TIMP3 and the MMPs were observed both in vitro and in vivo, in murine
and human models. The network of MMPs and TIMPs (the natural MMP inhibitors) plays
a major role in tumor progression in different cancers, including colon cancer, and it has
long been considered an area for therapeutic intervention. MMPs and TIMPs are now
understood to play key roles in a variety of biological processes aside from their bestknown role in matrix degradation, including growth factor receptor signaling, regulation
of angiogenesis, apoptosis and cancers 313,314 .

We have found that CDK8 inhibition in murine CT26 cells downregulates MMP3,
which is highly expressed in mouse CT26 cells, as well as MMP10 and MMP13, which are
expressed at much lower levels. CDK8 inhibition in a panel of human colon cancer cell
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lines suppressed the expression of another metastasis-associated MMP, MMP9;
remarkably, MMP3 acts as a proteolytic activator of MMP9 315. These results indicate that
CDK8 affects the expression of specific metastasis-associated MMPs in colon cancer cells.
MMP3 knockdown strongly increased the mouse survival of liver metastasis and
diminished the relative anti-metastatic effect of CDK8 inhibition in CT26 cells, providing,
to the best of our knowledge, the first demonstration of a functional role of MMP3 in
colon cancer metastasis. CTNNB1 knockdown studies showed that CDK8 regulates MMP3
expression to a large extent through its effect on the wnt/β-catenin pathway. This
pathway was previously shown to be co-regulated by CDK8 in vitro 286,316 but to the best
of our knowledge, the present study provides the first example of an in vivo effect of
CDK8/19 kinase inhibitors on the wnt/β-catenin pathway.

Among CDK8-regulated genes, TIMP3 has been identified as a suppressor of
invasion, metastasis and angiogenesis in different types of cancer, including colorectal
cancers 298. TIMP3 inhibits both MMPs and a related ADAM protease family, which are
essential for angiogenesis and required for the dissemination and establishment of tumor
metastases317. Protease-mediated degradation of extracellular matrix (ECM) and capillary
basement membrane, provides not only the space for angiogenesis but also the tethered
growth factors, such as vascular endothelial growth factor (VEGF), are released from
ECM, which further promotes the secretion of MMPs, forming a positive feedback to
expand the angiogenesis process318. In support of the role in angiogenesis, TIMP3
expression was inversely correlated with the vessel density in the tumors of melanoma
patients319. TIMP3 also showed MMP-independent activity to inhibit VEGF-mediated
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angiogenesis by directly interrupting the binding between VEGF receptor-2 and VEGF and
blocking the downstream signaling pathway320,321. TIMP3 could also directly induce
apoptosis in epithelial cells322. TIMP3 has been demonstrated by several groups to play
important roles in colon cancer metastasis. With paired primary and liver metastatic
colorectal samples, genome-wide methylation analysis found that methylation
frequencies of TIMP3 increased gradually from stage I-III to liver metastasis323.
Consistently with this finding, another group discovered that the protein levels of TIMP3
were negatively related to staging in colon carcinoma, with the lowest expression in the
samples with lymph node metastasis324. Adenovirus mediated expression of TIMP3 in
CT26 cells, one of the mostly used colon cancer cell lines for metastasis studies,
significantly decreased both the size and the number of metastatic tumors in the liver325.
Also in human HCT116 colon cancer cell line, IncRNA BC032913 significantly inhibited
both lung and liver metastasis by upregulating TIMP3 expression326.

Induction of TIMP3 was the most consistent metastasis-relevant transcriptional
effect of CDK8 inhibition observed in all the tested murine and human colon cancer cell
lines. Furthermore, TIMP3 was induced even by the lowest tested concentrations of
Senexin B that showed no detectable effect on MMP expression. Both liver-derived
tumors and a CT26 derivative selected for increased propensity for liver metastasis 299
showed concurrent upregulation of CDK8 and downregulation of TIMP3. Furthermore,
TIMP3 overexpression, like CDK8 inhibition, had no significant effect on primary tumor
growth but increased mouse survival of liver metastatic disease and reduced the relative

91

effect of Senexin B on liver metastasis. These results suggest that TIMP3 is the primary
and most general mediator of the effects of CDK8 on tumor growth in the liver.

Notably, the later stages of liver metastatic growth require angiogenesis (which is
suppressed by TIMP3) and involve deposition of fibrosis-like matrix (susceptible to
proteinases) that restrains metastases. The growth of metastatic tumors could trigger a
response resembling wound healing in the liver, which causes deposition of fibrosis like
matrix to increase the "tightness" of tumor microenvironment and restrain the growth of
metastases. In the CT26 liver metastasis experiments, alpha-SMA, a reliable predicator
for fibrous tissue deposition327, showed positive staining at the edge between hepatic
tissue and metastatic tumors. The MMPs and other ECM-degrading proteinases are of
critical importance for metastatic tumor growth in the liver52. In fact, the divergent
effects of inhibition of CDK8 on the growth of the primary tumors and the metastatic
tumors in liver could be partially explained by the "tightness" theory. The primary tumor,
implanted s.c. or in the spleen or orthotopically, usually grows to a large size and has less
of the surface area relative to volume as compared to the metastatic tumor in liver and
also has relatively less fibrosis-like matrix to deal with. Consequently, the growth of
primary tumor is less affected by MMPs/TIMPs balance, while the metastatic tumor has
to expand its growth space by ECM-degrading proteinases, which are inhibited by TIMP3.

Regulation of TIMP3 by CDK8 was found to be mediated via the TGF-β/SMAD
pathway. The TGF-β/SMAD pathway was shown to be potentiated by CDK8 through
SMAD phosphorylation, which stimulates SMAD-driven transcription but also promotes
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the eventual degradation of SMADs 303. TGF-β/SMAD-regulated TIMP3 expression in
other cell types was found to be mediated via SMAD-responsive transcription of miR181b that directly targets TIMP3 301,302. We have found that miR-181b negatively
regulates TIMP3 expression in colon cancer cells and that CDK8 inhibition suppresses
miR-181b expression via the effects of CDK8 on SMAD-driven transcription. While there
are reports of microRNAs that regulate CDK8 expression, to the best of our knowledge,
this is the first example of a microRNA regulated by CDK8 and mediating its biological
activity. The mechanisms of positive regulation of transcription by CDK8 have been
elucidated in many cases 207,213,293,328. However, such is not the case for negative
regulation of gene expression by CDK8 in mammalian cells, where the only reported
mechanism was accelerated degradation of CDK8-phosphorylated transcription factors
329.

Our findings raise the possibility that positive regulation of microRNAs could be an

important mechanism for negative regulation of gene expression by CDK8.

BMP-4, a member of the TGF-β/BMP family, is universally upregulated in colon
cancer cells and tissues 330 indicating that the TGF-β/SMAD pathway is commonly
activated in colon cancers. This pathway has been implicated in the metastatic
phenotype of a subset of colon cancers 331 and our data demonstrate that SMAD4
knockdown in the CT26 model selectively inhibits hepatic metastasis, while having no
effect on cell growth in vitro or primary tumor growth. The effects of SMAD4 and CDK8
knockdowns (or CDK8/19 kinase inhibition) were remarkably similar, both qualitatively
and quantitatively (much more similar than the effects of CDK8 and -catenin
knockdown), which, together with the data for the role of TGF-β/SMAD in CDK893

regulated TIMP3 expression, identifies CDK8/19 as a promising druggable mediator of the
in vivo tumor-promoting effects of the TGF-β/SMAD pathway.

Both CDK8 knockdown in tumor cells and systemic treatment of animals with
CDK8 kinase inhibitor strongly suppressed colon cancer hepatic metastasis but had no
significant effect on primary tumor growth. These similarities indicate that the role of
CDK8 in colon cancer metastasis is at least in part cell-autonomous. However, we also
saw that treatment of animals with Senexin B had a much weaker but still significant
effect on hepatic metastasis of tumors with CDK8 knockdown. While we cannot exclude
that this effect is due to the low levels of CDK8 (or CDK19) remaining in the knockdown
cells, the most apparent interpretation of this result is that a part of the anti-metastatic
effect of the CDK8 inhibitor is non-cell-autonomous and is exerted through the effects of
CDK8/19 inhibition on the tumor microenvironment or the immune system. As a
plausible mechanism, CDK8 was reported to be a negative mediator of tumor surveillance
activities of natural killer (NK) cells, and CDK8 knockdown increased such activities 332.
Such potential effects of CDK8 on the stromal microenvironment will be investigated in
future studies.

The mechanism of the potentiation of hepatic metastasis by CDK8, via the
regulation of MMP and TIMP3 expression, is summarized in Fig. 3.25. CDK8 potentiates
MMP expression primarily through its effects on /wnt/β-catenin mediated transcription.
At the same time, CDK8, through its potentiating effect on the TGF-β/SMAD pathway,
stimulates the expression of miR-181b, which suppresses TIMP3 expression. Inhibition of
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CDK8 suppresses the expression of both MMPs and miR-181b, allowing the expression of
TIMP3. TIMP3 production inhibits a broad spectrum of MMPs, suppressing metastatic
growth of colon cancer cells in the liver. Given the major contribution of hepatic
metastasis to colon cancer mortality, the metastasis-suppressing effects of CDK8
inhibition warrant exploring the use of CDK8-targeting drugs for the treatment of hepatic
metastasis of colon cancer. Furthermore, CDK8 inhibitors may potentially be useful in
other therapeutic settings that involve TGF-β/SMAD and wnt/β-catenin pathways.

FIGURE 3.25. The effects of CDK8 inhibition on metastatic tumor growth liver.
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in colon cancer cells inhibits TIMP3 and activates matrix metalloproteinases gene
expression, reshaping the microenvironment and stimulating metastatic growth in the
liver.
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MATERIALS AND METHODS
(all the reagents and resources can be found in Table.4.1)
TABLE 4.1 Key reagents and resources
REAGENT or RESOURCE
Antibodies
Anti-CDK8
Anti-CDK19
Anti-SMAD4
Anti-β-Catenin
Anti-TIMP3
Anti-MMP3
Anti-β-Actin
HRP-anti-goat IgG
HRP-anti-rabbit IgG
HRP-anti-mouse IgG
Alexa Fluor® 488-anti-rabbit IgG
Alexa Fluor® 594-anti-rabbit IgG

SOURCE

IDENTIFIER or SEQUENCE

SantaCruz
Sigma
Cell Signaling
Cell Signaling
Abcam
ThermoFisher
Scientific
Cell Signaling
SantaCruz
ThermoFisher
Scientific
ThermoFisher
Scientific
ThermoFisher
Scientific
ThermoFisher
Scientific

Cat#sc-1521
Cat#HPA007053
Cat#9515s
Cat#9587s
Cat#ab39184
Cat#MA5-17123

Bacterial and Virus Strains
One Shot® Stbl3™ Competent E.
ThermoFisher
coli
Scientific
Chemicals, Peptides, and Recombinant Proteins
Senexin B
Critical Commercial Assays
MycoAlert™ Mycoplasma
Detection Kit
RNeasy Mini Kit
iScript cDNA synthesis kit

Cat#3700
Cat#sc-2020
Cat#31460
Cat#31430
Cat#A-21206
Cat#A-21203

Cat#C737303

Senex Biotechnology
Lonza

Cat#LT07

Qiagen
Bio-Rad Laboratories

Cat#74106
Cat#1708891
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iTaqTM Universal SYBR® Green
Supermix
QiaQuick Gel Extraction Kit
CloneDirect™ Rapid Ligation Kit
Lipofectamine™ 3000
SureBeads Protein G Mag beads
DC Protein Assay Kit
E. coli Poly(A) Polymerase
Tetro Reverse Transcriptase kit
RNA picochip and reagents,
Bioanalyzer 2100
DNA 7500 chip and reagents,
Bioanalyzer 2100
Experimental Models: Cell Lines
CT26
HCT-116
LoVo
SW620
SW480
SW948
SW48
DLD-1
HT-29
SW116
HCT-15
293FT

Bio-Rad Laboratories

Cat#172-5124

Qiagen
Lucigen
ThermoFisher
Scientific
Bio-Rad Laboratories
Bio-Rad Laboratories
New England BioLabs
Bioline

Cat#28706
Cat#40020
Cat#L3000015
Cat#1614023
Cat#5000116
Cat#M0276
Cat#BIO-65050

ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ATCC
ThermoFisher
Scientific
Experimental Models: Organisms/Strains

CRL2638
CRL-247
CRL-229
CRL-227
CRL-228
CRL-237
CRL-231
CCL-221
HTB-38
CCL-233
CCL-225
R70007

Mouse: BALB/cJ

The Jackson
Laboratory
Mouse: Athymic nude (nu/nu)
The Jackson
Laboratory
Recombinant DNA: Vectors and Oligonucleotides

Stock No: 000651

hTIMP3-TGA-XbaI

This paper

hTIMP3-ATG-XbaI

This paper

pLenti6-TR

Thermo Fisher
Scientific
Addgene

TCAGGTCTAGATCAGGGG
TCTGTGGCATTGATGATG
TCAGGTCTAGAGCGGCAA
TGACCCCTTGGCTCGGGC
TCA
Cat# V48020

pRK5M-TIMP3
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Stock No: 002019

Plasmid #31715

Tet-pLKO-puro
shCDK8-1
shCDK8-2
shCDK19-1
shCDK19-2
shMMP3-1
shMMP3-2
shMMP3-3
shSMAD4-1
shSMAD4-2
shSMAD4-3
shSTAT1-1
shSTAT1-2
shCTNNB1-1
shCTNNB1-2
human shCDK8

Addgene
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
This paper

Mmu-miR-181-5p-mimic
miRIDIAN microRNA mmu-miR181b-5p hairpin inhibitor
Mimic negative control #1
Software and Algorithms
GraphPad Prism 5
SurvExpress
For the Kaplan-Meier study with
clinical data
Microarray data analysis

Dharmacon
Dharmacon

Plasmid #21915
TRCN0000322327
TRCN0000322410
TRCN0000023283
TRCN0000360760
TRCN0000031237
TRCN0000348486
TRCN000031234
TRCN0000025885
TRCN0000025900
TRCN0000362660
TRCN0000054924
TRCN0000054926
TRCN0000012688
TRCN0000012692
GCTTCCAAGTTGTACCTAT
TT
C-310587-07-0002
IH-310587-08-0002

Dharmacon

CN-001000-01-05

GraphPad Software
Aguirre-Gamboa et al.,
2013

Prism 5
http://bioinformatica.mt
y.itesm.mx:8080/Biomat
ec/SurvivaX.jsp
Expression Console

shRNA design

Thermo Fisher
Scientific
Broad Institute

https://portals.broadinsti
tute.org/gpp/public/seq/
search

Cell Lines and culture
CT26 mouse colon cancer cells were a gift from Dr. Maria Marjorette (Marj) Pena
(University of South Carolina, Columbia, SC), HCT116, Lovo, SW480, SW620, DLD-1,
SW948 and HEK293-FT cells were obtained from American Type Culture Collection (ATCC,
Manassas, VA). CT26 cells were maintained in RPMI-1640 (ThermoFisher Scientific,
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Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Atlanta Biologics, Flowery
Branch, GA, USA), 1% penicillin-streptomycin and 2mM L-glutamine (VWR, Radnor, PA,
USA). HCT116, Lovo, SW480, SW620, DLD-1, SW948 and HEK293-FT cells were
maintained in DMEM-high glucose media (Thermo Fisher Scientific) with 10% FBS, 1%
penicillin-streptomycin and 2 mM L-glutamine. All cell lines were routinely confirmed to
be free of Mycoplasma (MycoAlert PLUS mycoplasma detection kit (Lonza, Walkersville,
MD, USA). Senexin B and Senexin B dimaleate were from Senex Biotechnology
(Columbia, SC, USA).
Cell passage
Usually, 1 million cells were grown as adherent monolayers in VWR® Tissue
Culture Dishes 100 mm, in 5% CO2 at 37°C. Cells were split when they reached 80-90%
confluence. Briefly, media was aspirated from the culture dish. Cells were rinsed with PBS
to remove residual serum; 4 ml trypsin, (trypsin 0.05% w/EDTA) (Thermo Fisher Scientific)
was added onto the cells and shaken back and forth for a while and then aspirated. The
cells were incubated in the incubator for detachment. It usually took 3-5 min to complete
this process and check under the microscope if necessary. Once cells had detached,
trypsin was inactivated by the addition of 10 ml medium containing serum. The cells in
the medium were thoroughly pipetted to obtain single cell suspension. The suspension of
cells was applied for cell counting. Briefly, 10 μl cell suspension was added into cell
counter slides (Bio-Rad) and then analyzed by the TC10 Automated Cell Counter (BioRad). The proper number of cells were used in experimental analysis or continuous cell
culture.
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Cell freezing
Freezing media was prepared by mix 10% dimethyl sulphoxide (DMSO; Sigma
Aldrich) and 90% FBS. Cells were detached with trypsin as described before. 10 million of
cells were spin down at 250 g for 5 minutes. The pelleted cells were suspended in 10 ml
freezing media on ice. Aliquots at 1 ml were transferred to labelled cryovials (WHEATON
CryoELITE, VWR) and frozen at -80°C overnight. The frozen cells can be kept at -80°C for
months and kept in liquid nitrogen for years.
Cell recovery
The frozen cells can be recovered for cell culture by thawing process. The frozen
cells were put on dry ice and brought to the tissue culture room. 10 ml pre-warmed cell
growth medium was added into p100 dish. Cells were thawed in the thermostatic bath
set at 37 °C and transferred to the growth medium immediately when the ice thawed.
Cells were kept in the incubator overnight. The medium with DMSO and dead cells was
changed with fresh growth medium next day.
In vitro cell growth test
For in vitro cell growth test, 1 x 10^5 cells were seeded into p100 dish with the
corresponding cell culture medium. Senexin B or DMSO at indicated concentration was
added to culture medium at the same time. Cell numbers were recorded every day until
the cell reach 100% confluence.
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Colony assay
p100 plate was coated with 25 μg/ml of PEI at final concentration for 5 min late
and rinsed twice with PBS. 1000 single cell suspension were seeded into the coated plate
w/o Senexin B at 1 μM. Culture medium was aspirated when the diameter of colony was
around 1 mm. The colony was washed once with PBS and treated with 4% formaldehyde
for 10 min and rinsed with PBS one time. Colonies were stained with 0.25% R250
Coomassie bright blue solution for 5 min and the residual Coomassie was removed
running tap water. The images were captured via ChemiDoc™Touch Imaging System
(BioRad, USA). Colony number and size were calculated via imagej.

Western blot
1 million of cells were seeded in p100 plates and were cultured in the
corresponding growth medium for 24h before protein extraction. For the Senexin B
treatment, 0.5 million of cells were seeded in 6-well plates and cultured for 24h and then
Senexin B or DMSO as control were added into the medium and incubated for another 24
h, and then the cells were applied for the following protein extraction. Briefly, growth
media was aspirated and the cells were washed twice in ice cold PBS. Cells were
subsequently lysed in 0.5 ml 1x RIPA Buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% NP-40 1% sodium deoxycholate, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) plus Halt
Protease Inhibitor cocktails (Thermo Scientific). The cell lysates were gathered with a
plastic cell CytoOne fixed blade scraper (USA Scientific) and transferred into the 1.5
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Eppendorf tube and kept on ice. The DNA binding proteins were further released by
ultrasonication shearing on ice. The lysate was centrifugated at 4°C and 14,000 rpm for
10 min and transferred to a fresh 1.5ml.
The total protein concentration of the lysate was calculated using the DC™
Protein Assay (BioRad, USA). Series dilution of BSA (bovine serum albumin) in RIPA buffer,
10 mg/ml, 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml and 0 mg/ml, were used as standard protein
concentration. 5 µl cell lysates were loaded into the wells of 96-well plate (CytoOne NonTreated, USA Scientific). 25 µl reagent A with 0.5 µl reagent C was added into the wells
with sample. 200 µl reagent C was added and mixed thoroughly. After 15 min incubation
in the dark area at room temperature, the absorbance at 750 nm was measured iMark™
Microplate Absorbance Reader. The concentration of cell lysate was calculated by the
equation gotten from the standard curve.
10 or 12 % Sodium Dodecyl Sulphate Polyacrylamide (SDS-PAGE) gels made in
accordance with the recipe from Cold Spring Harbor Protocols. samples with 50 µg
protein were mixed thoroughly with loading buffer, with 10 % glycerol, 60 mM Tris/HCl
pH 6.8, 2 % SDS, 0.01 % bromophenol blue, 1 % beta-mercaptoethanol at final point. The
mixture was heated in the PCR machine for 10 min at 99°C to denature protein. In the
first well of the polyacrylamide gel, 7 μl protein marker, Precision Plus Protein™ Dual
Color Standards (BioRad, USA), was loaded. In the subsequent wells, equal amounts of
the sample proteins of interest were loaded. Electrophosesis was carried out in 1X
running buffer (25 mM Tris-HCl, 200 mM glycine, 0.1 % SDS, pH 8.8) at 100V until the
protein of interest reach the middle of the whole gel as indicated by the protein marker.
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The fractionated proteins were subsequently transferred onto Immun-Blot® PVDF
Membrane (BioRad, USA). Briefly, the PVDF membrane was activated by methanol for 1
min. The transfer cassette was settled up by putting fiber pad, filter paper, FVDF
membrane, gel, filter paper and fiber pad from positive electrode to negative electrode.
The cassette was then immersed in transfer buffer (25 mM Tris, 192 mM Glycine, 20%
(v/v) methanol, pH ~8.3). 100V electricity was applied for 90 min at 4°C.
The PVDF membrane with transferred proteins was blocked with 1% BSA in TBST
(200 mM Tris, 1.5 M NaCl, 0.05 % (v/v) Tween 20, pH ~7.4) for 1 hour at room
temperature. The membrane was subsequently incubated with primary antibody in 1%
BSA in TBST over night at 1% BSA in TBST. The primary antibodies used were : CDK8 (sc1521, SantaCruz, USA), CDK19 (HPA007053, Sigma-Aldrich), SMAD4 (9515s, Cell Signaling
Technology, Danvers, MA, USA), Phospho-STAT1 (ser727) (8826s, Cell Signaling
Technology, Danvers, MA, USA), STAT1 (9172s, Cell Signaling Technology, Danvers, MA,
USA), β-Catenin (9587s, Cell Signaling Technology, Danvers, MA, USA), Timp3 ( ab39184,
Abcam, USA), GAPDH (#5174, Cell Signaling Technology, Danvers, MA, USA). The
membrane was washed thoroughly with TBST for 10 min for 3 times and then incubated
with horseradish peroxidase-conjugated secondary antibody in 1% BSA in TBST for 1 hour
at room temperature. The secondary antibodies used were: anti-goat (sc-2020,
SantaCruz), anti-rabbit (#31460, ThermoFisher Scientific) or anti-mouse (31430,
ThermoFisher Scientific) secondary antibodies. After 3 washing steps with TBST, 10 min
for each, the membrane was incubated with Western Lightning Plus-ECL (PerkinElmer
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Inc.) for 5 min. The luminescence was detected via ChemiDoc™Touch Imaging System
(BioRad, USA). The signal strength was measured via Image Lab 5.2.1 (BioRad, USA).

RNA extraction, reverse transcription, and q-PCR (Quantitative real-time PCR)
0.2 million of cells were seeded in 6-well plates and were cultured in the
corresponding growth medium for 24h before RNA extraction. For the Senexin B
treatment, 0.1 million of cells were seeded in 6-well plates and cultured for 24h and then
Senexin B or DMSO as control were added into the medium and incubated for another 24
h, and then the cells were applied for the following RNA extraction. The RNA extraction
was performed with RNeasy Mini Kit (Qiagen, Hilden, Germany) and all the reagents was
prepared following the instructions. Briefly, cell culture media was removed and 350μl
RLT/ β -ME cell Lysis buffer was added directly to the cells. The plate was rocked a few
times to let the Lysis buffer cover all the area and left at room temperature for 3~5min to
ensure complete Lysis. The 350ul lysate was transferred to the QIAshredder spin column
for homogenization by centrifuged at 13,000 rpm for 2 min. The filtrated lysate was
mixed with 1 volume (350μl) of 70% ethanol pipetted up-and-down 3~4 times. The
mixture was then loaded to RNeasy Mini column and centrifuged at 14,000 rpm for 30
sec. The flow-through was discarded. 700 µl buffer RW1 was loaded to RNeasy Mini
column and centrifuged at 14,000 rpm for 30 sec. 700 µl buffer RPE was loaded to
RNeasy Mini column and centrifuged at 14,000 rpm for 30 sec. The column was
transferred to another new collecting tube and centrifuged at 14,000 rpm for 2 min to
make sure there was no RPE carryover. The column was carefully transfer to another new
1.5ml collecting tube and 40µl water (RNase-free) was loaded and incubated at room
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temperature for 2 min. The RNA was collected by centrifugation at 14,000 rpm for 2 min.
The RNA concentration was measured with NanoDrop Spectrophotometer (Thermo
Scientific). RNA purity assessed using the A260/A280 ratio method with a ratio >2
deemed acceptable.
1 µg of total RNA was used to generate cDNA using iScript cDNA synthesis kit
(BioRad, Hercules, CA, USA). Briefly, 1 µg of total RNA at 10 µl was mixed with 5 µl water
and 2 µl reaction buffer and 1 µl enzyme in the PCR tube. Bio-Rad T100TM Thermal Cycler
was used to process the RNA to DNA reaction by incubating the reaction mix at 25°C for 5
min, 45°C for 30 min, 85°C for 5 min and held at 4°C. The 20 µl obtained cDNA was
diluted with 180 µl nucleotidase free water and ready for the qPCR test.
qPCR was performed with the machine Bio-Rad CFX384 Touch™ Real-Time PCR
Detection System. Briefly, 3.3 µl diluted cDNA was mixed with 4.95 µl iTaqTM Universal
SYBR® Green Supermix and 0.5 µl 10 µM primers (forward and reverse) and 3.95 µl
nucleotidase free water. The mixed reaction solution was put into the qPCR machine and
incubated at 95°C 3 min for priming and then followed with incubated at 95°C for 5
second and 60 °C for 30 second, the late two steps were repeated for 40 cycles. After the
amplification steps, the sample was incubated at 65 °C and the temperature was
increased by 0.5°C per second to 95°C to get melting curve for each amplified DNA
fragment. Ct (threshold cycle), the intersection between an amplification curve and a
threshold line, was used to determine the template amount in each sample. The qPCR
data were analyzed by the double delta Ct method. Basically, the average of the Ct values
for the housekeeping gene and the gene being tested in the experimental and control
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conditions were used. The 4 values are Gene being Tested Experimental (TE), Gene being
Tested Control (TC), Housekeeping Gene Experimental (HE), and Housekeeping Gene
Control (HC). The differences between TE and HE (TE-HE) and TC and HC (TC-HC) were
the ΔCt values for the experimental (ΔCTE) and control (ΔCTC) conditions, respectively.
The difference between ΔCTE and ΔCTC (ΔCTE-ΔCTC) was Double Delta Ct Value (ΔΔCt).
The gene expression fold change was 2^-ΔΔCt. In some case, the gene expression level
was described as the expression level relative to the certain housekeeping gene and
calculated as 2^(HE-TE). All the qPCR tests were run in triplicate.
Primers used for real-time PCR are listed in Supplemental Table 4.2.
TABLE 4.2 QPCR primer sequences
mSMAD4-F

ACACCAACAAGTAACGATGCC

mSMAD4-R

GCAAAGGTTTCACTTTCCCCA

mCTNNB1-F

CGCTGCTCATCCCACTAATGTC

mCTNNB1-R

TCCGCGTCATCCTGATAGTTAATC

mCDK8-F

CGGGTCGAGGACCTGTTTG

mCDK8-R

TGCCGACATAGAAATTCCAGTTC

mCDK19-F

GGTCAAGCCTGACAGCAAAGT

mCDK19-R

TTCCTGGAAGTAAGGGTCCTG

mMMP10-F

GAGCCACTAGCCATCCTGG

mMMP10-R

CTGAGCAAGATCCATGCTTGG

mMMP13-F

TGTTTGCAGAGCACTACTTGAA
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mSMAD4

mCTNNB1

mCDK8

mCDK19

mMMP10

mMMP13

mMMP13-R

CAGTCACCTCTAAGCCAAAGAAA

mMMP3-F

TTAAAGACAGGCACTTTTGGCG

mMMP3-R

CCCTCGTATAGCCCAGAACT

mRPL13A-F

GGGCAGGTTCTGGTATTGGAT

mRPL13A-R

GGCTCGGAAATGGTAGGGG

mSTAT1-1-f

GCTGCCTATGATGTCTCGTTT

mSTAT1-1-r

TGCTTTTCCGTATGTTGTGCT

mTIMP3-F

CTTCTGCAACTCCGACATCGT

mTIMP3-R

GGGGCATCTTACTGAAGCCTC

RPL13A-F

GGCCCAGCAGTACCTGTTTA

RPL13A-R

AGATGGCGGAGGTGCAG

TIMP3-F

GGTGAAGCCTCGGTACATCT

TIMP3-R

AGGACGCCTTCTGCAACTC

CDK19-F

GTTTCACCGTGCATCAAAAGC

CDK19-R

ACCCAATTTGCATGGAGGTAATG

CDK8-F

AAGTTGGCCGAGGCACTTAT

CDK8-R

ATGCCGACATAGAGATCCCA

MMP2-F

AAGAAGTAGCTGTGACCGCC

MMP2-R

TTGCTGGAGACAAATTCTGG

MMP3-F

TGAAAGAGACCCAGGGAGTG

MMP3-R

AGGGATTAATGGAGATGCCC
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mMMP3

mRPL13A

mSTAT1

mTIMP3

hRPL13A

hTIMP3

hCDK19

hCDK8

hMMP2

hMMP3

MMP7-F

GCATCTCCTTGAGTTTGGCT

MMP7-R

GAGCTACAGTGGGAACAGGC

MMP9-F

ACGACGTCTTCCAGTACCGA

MMP9-R

TTGGTCCACCTGGTTCAACT

MMP10-F

CTGATGGCCCAGAACTCATT

MMP10-R

ACTGGAACCCTGAACCTGAA

MMP13-F

CACCAATTCCTGGGAAGTCT

MMP13-R

GCAGCTGTTCACTTTGAGGA

mmir-21a

TGTACCACCTTGTCGGATAGCTTATC

miRNA PCR

mmir-181a-1

GGTTGCTTCAGTGAACATTCAAC

miRNA PCR

mmir-181a-2

CCATGGAACATTCAACGCTGTCG

miRNA PCR

mmir-181b-1

AGGTCACAATCAACATTCATTGC

miRNA PCR

mmir-181b-2

TTGATGGCTGCACTCAACATTCAT

miRNA PCR

mmir-181c

GCCAAGGGTTTGGGGGAACATTC

miRNA PCR

mmir-181d

ACAATTAACATTCATTGTTGTCG

miRNA PCR

mmir-21b

TTTGAGGATACTCTTGCATATGGA

miRNA PCR

mmir-125b-1

TGCGCTCCCCTCAGTCCCTGAG

miRNA PCR

mmir-125b-2

GCCTAGTCCCTGAGACCCTAAC

miRNA PCR

mmir-712

TCTCCGCTTCTCCTTCACCCGGGC

miRNA PCR

URT

AACGAGACGACGACAGACTTTTTTTTTTTTTTT

miRNA PCR

UPCR

AACGAGACGACGACAGACTTT

miRNA PCR
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hMMP7

hMMP9

hMMP10

hMMP13

Gene expression modification
Transforming competent cells
30 μl One Shot® Stbl3™ Chemically Competent E. coli (ThermoFisher Scientific)
mixed with about 100 ng plasmids was subjected to heat-shock treatment by incubation
on ice for 20 minutes followed by incubation at 42°C for 45 seconds and then put on ice
immediately for a further 2 min. The DNA/bacteria mix was then transferred into 450μl of
sterile LB broth and incubated at 37°C. After 1 hour, 10 μl and 100 μl of E. coli was
seeded and spread on pre-warmed LB agar plates (containing 50μg/ml ampicillin from
Sigma-Aldrich) separately which were then incubated overnight at 37°C. The following
day, individual bacterial colonies were transferred to separate falcons containing LB
broth with ampicillin (50μg/ml) and then incubated with shaking in the incubator-shaker
overnight at 37°C. The following day, bacterial cells were spin down at 3000rpm for 10
min.
Plasmid DNA was extracted from the bacterial pellet using the QIAprep® Miniprep
kit (Qiagen) following the manufacturer’s instructions. DNA was eluted in 50μl of
nuclease-free water, quantified using a Nanodrop 1000 spectrophotometer (Thermo
Scientific) and stored at -20°C.
Plasmid construction
To construct the plasmid pLenti6-hTIMP3, which is suitable for lentivirus
transduction, 2 µg pLenti6-TR plasmid (Thermo Fisher Scientific) was digested with
FastDigest XbaI (Thermo Fisher Scientific) at 37°C for 1 hour. The product was loaded to
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the 0.8% agarose gel for separation. The bigger fragment was recycled by the QiaQuick
Gel Extraction Kit (Qiagen) and the was dephosphorylated by Antarctic Phosphatase (New
England Biolabs®. Inc) and the product was labelled as pLenti6/XbaI/AP. Human TIMP3
cDNA fragment was amplified from pRK5M-TIMP3 (31715, Addgene) by PCR with the
primers. The PCR product was digested with FastDigest XbaI (Thermo Fisher Scientific) at
37°C for 1 hour and then loaded to 0.8% agarose gel for DNA separation. The DNA band
was recycled with QiaQuick Gel Extraction Kit and labelled as hTIMP3/Xbal.
pLenti6/XbaI/AP and hTIMP3/Xbal was ligated by CloneDirect™ Rapid Ligation Kit
(Lucigen). 2uL of ligation was used to do bacteria transformation. The plasmids from the
clones were checked with Hind III digestion and Clal plus Pst I digestion. The correct
plasmid was named as pLenti6-TIMP3.
The shRNAs plasmids that have the highest adjusted scores according to the
Genetic Perturbation Platform (broad institute) were purchased from Sigma-Aldrich.
Lentivirus production
All the procedure of lentivirus production was performed as BIO-HAEZARD II level.
The pipette or tip used were soaked in 10% bleach for at least half hour before disposed
to regular orange biohazard bags. The media containing virus was neutralized by 10%
bleach (at 1:1 ratio) for at least half hour before being aspirated into regular liquid
disposal. 5 million of 293FT cells were seeded into the PEI (polyethylenimine)
(SigmaAldich) pre-coated p100 dish. The second day, DNA mixture (0.25 μg pCMV-dR8.91
and 0.075 μg pCMV-VSV-G and 5 μg lentiviral construct) was transfected into 293FT cells
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via Lipofectamine 3000 Reagent (ThermoFisher Scientific). 8 h after transfection, the
medium was changed. Another two days late, the virus-containing media were collected
and filtered with 0.22 μm filter. The virus- containing medium was ready for cell
transduction or being stored at -80°C.
Lentivirus transduction
Before the lentivirus transduction, the target cells were challenged by different
concentration of puromycin (Sigma-Aldrich) or blasticindin (Sigma-Aldrich) from 1 μg/ml
to 10 μg/ml. the lowest concentration that killed all the cells in one week was used in the
following selection. The cells were also challenged by different concentration of
hexadimethrine bromide (Sigma-Aldrich) and the highest concentration that left the cells
growth normally in 24 h was used in the following experiment. For the transduction, 0.1
million of CT26 cells were seeded into 6-well plate. A series of dilution of collection of
virus- containing medium were applied onto the cells with hexadimethrine bromide to a
final concentration of 8 µg/ml. 8 h after the transduction of lentivirus, the lentiviruscontaining medium will be collected and lentivirus inactivated by mixing with 10% final
concentration of bleach for 12 h. The transduced cells will be cultured in normal growth
medium for 48 h. After that, puromycin will be added into the growth medium at 10
µg/ml, which was based on our previous puromycin killing curve in CT26 cells. After three
rounds of puromycin treatment, 3 days for each round, the stable knockdown cells will
be cultured in puromycin-free medium for one week and then frozen in 20 vials. For the
overexpression of hTIMP3, the transduced cells were selected with 5 µg/ml blasticindin
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for three rounds of puromycin treatment, 3 days for each round. The obtained cells were
checked by qPCR and western blot assays for knockdown or overexpression efficacy.

Microarray analysis
Total cellular RNA from different kinds of cells with different treatment was
extracted as described previously and RNA quality was tested using Bioanalyser (Agilent,
Santa Clara, CA, USA). Microarray analysis of CT26-plko.1 (CT26 cells shRNA vector
control) and CT26-shCDK8-1 (CT26 cells with stable CDK8 knockdown by shRNA, number
1) was performed on Illumina expression microarray platform by Proteogenomics Facility
at Medical University of South Carolina. Microarray analysis for the comparison between
CT26 cells treated with DMSO and 5 µM Senexin B for 24 hour and the comparison
between CT26-plko.1 and CT26-shCDK8-2 (CT26 cells with stable CDK8 knockdown by
shRNA, number 2) were performed via Affymetrix Mouse gene 2.0 X ST arrays, conducted
by Microarray Core Facility of College of Pharmacy at the University of South Carolina.
Microarray data were analyzed using Expression Console (Thermo Fisher Scientific). A
subset of identified genes was validated in biological triplicates by q-PCR.

In vivo experiments
All animal studies were performed according to guidelines established by the
Institutional Animal Care and Use Committee (IACUC) at the University of South Carolina
(Columbia, SC). All instruments used were autoclaved and then sterilized by glass bead
sterilization in between surgeries. The female BALB/cJ mice at 6 to 7 weeks were bought
from The Jackson Laboratory and the male nude mice at 6 to 7 weeks were purchased
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from Taconic Biosciences. The animals were kept at the animal facility at the University of
South Carolina. Animals were free access to the water and food and the cycle of day and
night was 12 h to 12 h.
Metastasis model
The female BALB/cJ mice (nude mice for the HCT116 cells) were anesthetized in
an induction chamber with 2-5% isoflurane in oxygen administered by inhalation and
delivered by an EZ anesthesia vaporizer. The depth of anesthesia is monitored by
observing for the lack of response to a toe pinch and lack of palprebral reflex. The mice
were then transferred to the surgical table. Anesthesia was maintained in 2% isoflurane
in oxygen throughout the duration of the surgery using a nose cone. The abdominal area
above spleen was shaved to remove hair prior to surgery and sterilized with 70% ethanol
swabs prior to incision. Buprenorphine was admnistered i.p. (0.05-0.1 mg/kg) as preemptive analgesia prior to surgery. A small abdominal incision about 1 cm above the
spleen was made and the wound margins was covered with sterile gauze moistened with
phosphate buffered saline (PBS) to prevent peritoneal spread of cells and drying up. The
spleen was exposed through the incision; 0.2 × 10^5 CT26 cells in 20 μl of DMEM (1 x
10^6 HCT116 cells in 100 μl of DMEM) were injected into the spleen via a 33-gauge
needle. Depending on the experiment we will then perform one of the following
procedures:
a) For routine metastasis study on the model with CT26 cell injection, the site of injection
was sealed with Tissue Adhesive (3M Vetbond™) to prevent tumor cell escape and
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leakage. The spleen was rinsed successively with PBS and 70% ethanol to remove any
cells that may have potentially leaked out during injection.
b) For survival experiment on the model with CT26 cells injection and routine metastasis
study with HCT116 cell injection, the spleen was removed by splenectomy 1 min after the
injection of tumor cells into the spleen. The artery was tied off with a 4-0 suture (492A
Suture CP Medical) by looping through the mesentery and the mesentery and connective
tissue will be cauterized and the spleen removed.
The abdominal incision was then sutured in two layers by continuous suture with
a 6-0 absorbable suture (492A Suture CP Medical). After surgery, the mice were given
500 μl of saline to keep them hydrated. Mice were kept in cages placed on a heating pad
(maintained at 37°C) for recovery from anesthesia and are ambulatory within 5 - 10
minutes after the surgery. They were closely monitored for pain and discomfort and for
proper healing of incision, daily for one week post-surgery. Buprenorphine (0.05-0.1
mg/kg) was administered i.p. as needed.
Synograft s.c. model
The mice were anesthetized in an induction chamber with 2-5% isoflurane in
oxygen administered by inhalation and delivered by an EZ anesthesia vaporizer. The
depth of anesthesia is monitored by observing for the lack of response to a toe pinch and
lack of palprebral reflex. To establish synograft s.c. model, a single-cell suspension of 1.0
x 10^6 CT26 cells were obtained from 50%-70% confluent adherent cultures and
suspended in 100 μl of sterile PBS was injected s.c. into the flanks of 7 to 8 weeks old
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female BALB/cJ mice with a Sub-Q26G5/8 needle. Animals were allowed to recover on
the warm plate and then returned to cages. Tumor dimensions were measured using
calipers. To approximate the subcutaneous tumor size, the calipers was compressed on
the skin slightly but not so tightly as to grip the subcutaneous mass. The maximal
dimension of the tumor was recorded as L. The dimension crossing the L as W. The
formula: Volume = L x W x W/2 will be used. The volumes of growing tumors were
measured twice per week.
The delivery of Senexin B
For the s.c. synograft model: When the average tumor volume reached 100 mm3,
the mice were randomly grouped. Senexin B dimaleate was administered by gavage at 50
mg/kg doses (weight doses calculated for Senexin B dimaleate rather than free Senexin B)
in 6.25% 2 Hydroxypropyl β cyclodextrin, 1% Dextrose buffer (CD vehicle), b.i.d. or with
the vehicle control.
For the metastasis model: The treatment of this model was started at the first of
surgery, or as specifically indicated. There were several of methods of the delivery of
Senexin B were performed. Each of them was: mice were treated by daily i.p. injection of
Senexin B dichloride (40 mg/kg) in 10 mM citrate buffer, pH6, 150 mM NaCl or with
vehicle control; Senexin B dimaleate was administered by gavage at 50 mg/kg doses in CD
vehicle, b.i.d.; mice were treated with the control diet (Research Diets, D12450B) or the
Senexin B mixed in the diet at the concentration 0.4mg/g as low dosage and 1.4 mg/g as
high dosage; mice were treated with the combination of low dosage of diet with Senexin
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B and the Senexin B dimaleate administered by gavage at 50 mg/kg doses in CD vehicle
daily.
All animals were observed daily for tumor growth and morbidity, as well as sideeffects such as weight loss, diarrhea, and respiratory distress which may be associated
with the chemotherapeutic drugs. Animals were sacrificed at the end point of each part
of the study or if they are moribund, and if the tumors appear to significantly inhibit their
movement. Tumor burden was not allowed to exceed 10% of body weight or tumor size
reached around 2000 mm3. Any animal found to be moribund, cachectic, or unable to
obtain food or water, as well as those in which body weight has decreased by more than
20% compared with control animals, or more than 20% over a period of 7 days were
euthanized. Body condition will also be determined as tumor growth may cause body
weight to stay the same or even increase, but loss of muscle and subcutaneous fat may
lead to a marked loss of body condition. This will be evaluated through feeling the pelvis
and backbone, or if evidenced by a square tail due to muscle atrophy revealing the
square shape of the vertebrae.
The mice were sacrificed after anesthetization in the induction chamber 5%
isoflurane in oxygen administered by inhalation and delivered by an EZ anesthesia
vaporizer for 5 min. Half of the tumors or organs was kept into the 10% neutral buffered
Formalin (Sigma-Aldrich) overnight. The fixed tissue was processed as putting in 70%
ethanol for 1 hour, 95% ethanol for 1 hour, 100% ethanol for 1h ,100% ethanol for
another 1 h, xylene for 1 h, xylene for another 1 h, paraffin wax at 58°C for 1 h, paraffin
wax at 58°C for another 1 h and then embedded in the paraffin blocks. Tumor fragments
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or organs measuring 20-30 mg were snap frozen by putting into the liquid nitrogen for
RNA or protein analysis.

H&E staining
The H&E staining was performed by Instumentation Resource Facility at
University of South Carolina School of Medicine. Briefly, paraffin section containing the
tissue of interest was cut from the tissue blocks and placed on slide glass and then in the
slide holder. The slides were then deparaffinized and rehydrate by going through three
times of xylene for 10 min and three times of 100% ethanol for 1 min, 95% ethanol for 30
second, 75% ethanol for 30 second and in water for 1 min. After rehydratation, the slides
were put into the hematoxalin for 3 min and then put into the tap water for 5 min for
development and destained in acid ethanol (1 ml concentrated HCl + 400 ml 70%
ethanol) by dipping a few times. After washing with deionized water for 2 min, the slides
were transferred into eosin solution for 30 seconds and then transferred into 95%
ethanol and 100% ethanol for dehydration. The slides were then put into xylene for 15
min and repeat once. A drop of Permount (#SP15 100, Fisher Scientific) was put on the
stained tissue section and coverslip was used to cover and seal the staining. The H&E
staining images were acquired with Leica DM1000 LED microscope and Leica Application
Suite EZ. Tumor area quantification was performed by the software Image-Pro® Plus 6.0
and analyzed by ImageJ software.

118

Histology and Immunofluorescence (IF)
For IF staining, sections of tumor tissues (5 μm) were deparaffinized, rehydrated
as described in H&E staining. Antigen was retrieved by maintained in antigen retrieval
buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0) at 120 °C for 5 min. Slide was
blocked in PBS containing 5% goat serum and 0.3% Triton-X-100 for 1 h at room
temperature. Tissues were then incubated at 4°C overnight with primary antibody in
TBST with 1% goat serum. Secondary antibodies conjugated with Alexa Fluor 594
(targeting mouse) and with Alexa Fluor 488 (targeting rabbit) was used for 1 hour at
room temperature. After counterstaining in 300 nM DAPI in PBS for 1 min, sections were
mounted with 80% glycerol in PBS. Images were taken by Olympus IX81 and analyzed
using ImageJ.

RNA preparation from tissue
The sample of tissue or tumor at around 20-30 mg was homogenized in 1000 µl of
TRIzol® Reagent (Ambion® | Thermo Fisher Scientific) via homogenizer POWERGEN 125
(Fisher Scientific) and kept at room temperature for 5 min to permit complete
dissociation of the nucleoprotein complex. 0.2 ml of chloroform was used for
homogenization by shaking tube vigorously for 15 seconds. The sample was kept at room
temperature for 3 min and then centrifuged at 12,000 g for 15 min at 4 °C. The aqueous
phase of the sample was transferred into a new tube and mixed with 0.5 ml of 100%
isopropanol and then kept at room temperature for 10 min. the RNA pellet was spin
down by 12,000 g for 10 min at 4 °C and then washed with 75% ethanol for twice. After
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removal of the ethanol, 500 µl of RNase free water was added to resuspend the RNA
pellet. The A260/280 ratio of the RNA solution should > 1.9.

Protein preparation from tissue
For protein lysate preparation, 2 ml RIPA buffer with Protease Inhibitor cocktails
(Thermo Fisher Scientific) and 10 mM NaF and 10 mM NaVO3 was applied to 20 mg
sample. The sample was homogenized via homogenizer POWERGEN 125 (Fisher
Scientific). The debris was spin down by centrifugation at 14,000 g for 15 min at 4 °C. The
solution was transferred into a new tube and ready for western blot.

Statistical analysis
Most data were presented as mean ± standard error of the mean (SEM) of
biological replicates. Meta-analysis of clinical data was conducted using SurvExpress
(http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp). Survival data were
analyzed by Kaplan Meier survival curves and the comparisons were performed through
Log Rank test using GraphPad Prism 5 software. Statistical significance was tested using
unpaired Student’s t-test (two-tailed) and P values of less than 0.05 were considered
significant.
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